

See discussions, stats, and author profiles for this publication at: <https://www.researchgate.net/publication/355943225>

Psychedelics as Novel Therapeutics in Alzheimer's Disease: Rationale and Potential Mechanisms

Article in *Current Topics in Behavioral Neurosciences* · November 2021

DOI: 10.1007/7854_2021_267

CITATIONS

0

READS

39

5 authors, including:



Albert Garcia-Romeu

Johns Hopkins Medicine

48 PUBLICATIONS 1,399 CITATIONS

SEE PROFILE

Some of the authors of this publication are also working on these related projects:



Johns Hopkins Psilocybin Research Project [View project](#)

Psychedelics as Novel Therapeutics in Alzheimer’s Disease: Rationale and Potential Mechanisms



Albert Garcia-Romeu , Sean Darcy, Hillary Jackson, Toni White, and Paul Rosenberg

Contents

- 1 Introduction
 - 2 Pathophysiology and Etiology of Alzheimer’s Disease
 - 2.1 Decreased Serotonergic Neurotransmission in AD
 - 2.2 Loss of Synaptic Function in AD
 - 2.3 Key Signaling Pathways in AD
 - 2.4 Inflammation in AD
 - 2.5 Changes in Brain Metabolism and Functional Connectivity in AD
 - 2.6 Neuropsychiatric Comorbidities in AD
 - 3 Neurobiology of Psychedelics
 - 3.1 Data on the Role of 5-HT_{2A}R in Learning and Memory
 - 3.2 Psychoplastic Effects of Psychedelics and Related Signaling Pathways
 - 3.3 Psychedelics as Anti-inflammatory Agents
 - 3.4 Psychedelics’ Effects in Humans
 - 4 Rationale and Approaches for Researching Psychedelics in Patients with AD
 - 5 Conclusion
- References

Abstract Serotonin 2A receptor (5-HT_{2A}R) agonist “classic psychedelics” are drawing increasing interest as potential mental health treatments. Recent work suggests psychedelics can exert persisting anxiolytic and antidepressant effects

A. Garcia-Romeu (✉), S. Darcy, and H. Jackson
Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA

Center for Psychedelic and Consciousness Research, Johns Hopkins University School of Medicine, Baltimore, MD, USA
e-mail: agarci33@jhmi.edu; sdarcy2@jhu.edu; hjacks18@jhmi.edu

T. White and P. Rosenberg
Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA

Memory and Alzheimer’s Treatment Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA
e-mail: toni.white@som.umaryland.edu; prosenb9@jhmi.edu

lasting up to several months after a single administration. Data indicate acute subjective drug effects as important psychological factors involved in observed therapeutic benefits. Additionally, animal models have shown an important role for 5-HT_{2A}R agonists in modulating learning and memory function with relevance for Alzheimer's Disease (AD) and related dementias. A number of biological mechanisms of action are under investigation to elucidate 5-HT_{2A}R agonists' therapeutic potential, including enhanced neuroplasticity, anti-inflammatory effects, and alterations in brain functional connectivity. These diverse lines of research are reviewed here along with a discussion of AD pathophysiology and neuropsychiatric symptoms to highlight classic psychedelics as potential novel pharmacotherapies for patients with AD. Human clinical research suggests a possible role for high-dose psychedelic administration in symptomatic treatment of depressed mood and anxiety in early-stage AD. Preclinical data indicate a potential for low- or high-dose psychedelic treatment regimens to slow or reverse brain atrophy, enhance cognitive function, and slow progression of AD. In conclusion, rationale and potential approaches for preliminary research with psychedelics in patients with AD are presented, and ramifications of this line of investigation for development of novel AD treatments are discussed.

Keywords Alzheimer's disease · Dementia · Hallucinogen · Mild cognitive impairment (MCI) · Psilocybin · Psychedelic

1 Introduction

Alzheimer's Disease (AD) is a growing concern amid a rapidly increasing population aged 65 and older worldwide, and projected rising global life expectancy (He et al. 2016). Currently, more than five million adults in the USA and 36 million worldwide are living with AD, and this number is expected to triple by 2050 (Alzheimer's Association 2021). However, there has been little success in development of strategies for AD pharmacotherapy. Symptomatic treatment of AD with acetylcholinesterase inhibitors such as donepezil, rivastigmine, and galantamine has been available since the 1990s with modest benefits for some patients (Tayeb et al. 2012). The *N*-Methyl-*D*-aspartate (NMDA) antagonist memantine was approved for treating moderate to severe AD by the US Food and Drug Administration (FDA) in 2003, but to date no cure or well-established disease modifying treatment for AD is available, despite extensive research and drug development efforts involving over 240 failed candidate drugs (Dubois et al. 2014; Wimo et al. 2014). Although recent progress has been made toward developing novel antibody-based pharmacotherapies such as aducanumab (Sevigny et al. 2016) and donanemab (Mintun et al. 2021), controversy remains whether these will prove safe, accessible, and substantially effective treatments for patients with AD (Ayton 2021; Doggrell 2021; Knopman

et al. 2021). Given the enormous morbidity and mortality associated with AD, it is clear that novel approaches to AD treatment are urgently needed.

The past two decades have seen a resurgence in research involving hallucinogenic serotonin 2A receptor (5-HT_{2A}R) agonists, known as “classic psychedelics,” as potential treatments across a range of medical and mental health conditions. Preliminary studies in animals and humans suggest that classic psychedelics such as psilocybin, lysergic acid diethylamide (LSD), and the dimethyltryptamine (DMT) containing decoction ayahuasca may have promising antidepressant, anxiolytic, and antiaddictive properties (Garcia-Romeu et al. 2016). So much so, that the FDA has granted psilocybin “breakthrough therapy” designation as a potential treatment for major depressive disorder, with clinical trials of therapeutic safety and efficacy currently underway (Nichols 2020). To date, psychedelics’ psychological mechanisms of action appear related to acute subjective drug effects associated with positive therapeutic outcomes (Bogenschutz et al. 2015; Garcia-Romeu et al. 2014; Griffiths et al. 2016; Roseman et al. 2018; Ross et al. 2016). Additionally, preclinical and neuroimaging research indicate a number of compelling biological mechanisms of psychedelics related to stimulation of 5-HT_{2A}R and downstream signaling pathways relevant to AD. These mechanisms include promotion of structural and functional neuroplasticity (Catlow et al. 2013; Lima da Cruz et al. 2018; Ly et al. 2018), post-acute changes in key signaling pathways such as brain-derived neurotrophic factor (BDNF) (Hutten et al. 2021; Ly et al. 2018), anti-inflammatory effects (Flanagan and Nichols 2018), as well as acute and post-acute changes in brain functional connectivity (Barrett et al. 2020a, b; Carhart-Harris et al. 2012; Carhart-Harris et al. 2017; Preller et al., 2020). This review provides a detailed examination of potential mechanisms of classic psychedelics as possible treatments for patients with AD and describes the rationale for targeted investigation of psychedelics in patients with early AD (e.g., ClinicalTrials.gov NCT04123314).

2 Pathophysiology and Etiology of Alzheimer's Disease

Both normal aging and Alzheimer's Disease (AD) have been associated with decreased functional brain activity and connectivity (Dennis and Thompson 2014; Tomasi and Volkow 2012). Network hypersynchrony and abnormalities such as impaired default mode network (DMN) deactivation have been linked to cognitive dysfunction and implicated as potential targets for therapeutic intervention in AD (Palop and Mucke 2016). The neuropathological hallmarks that typically define AD are amyloid- β (A β) plaques, neurofibrillary tangles, and neuronal and synaptic loss (Serrano-Pozo et al. 2011a; Shoghi-Jadid et al. 2002). This neurodegeneration is associated with cognitive and functional decline typically starting with loss of episodic memory and progressing to include aphasia, apraxia, and agnosia (Butzlaff and Ponimaskin 2016; Weintraub et al. 2012). While amyloid is thought to be the “prime mover” in AD pathobiology, we are still ascertaining the mechanisms of progressive neurodegeneration, which likely include tau deposition as the next

phase, leading on to neuronal loss. A β accumulation has been suggested to facilitate formation of pathological tau, and together these seem to trigger additive neurotoxic effects functioning as a systemic feedback loop resulting in acute neuron death and synaptic dysfunction (Bloom 2014).

AD is thought to begin up to 20 years prior to symptoms with a lengthy preclinical, “prodromal” phase during which cleavage of Amyloid Precursor Protein (APP) by Beta-secretase 1 (BACE-1) and Gamma-secretase results in the aggregation of A β protein and A β plaques (Sperling et al. 2011). This accrual results in neurodegeneration in characteristic brain regions (including the hippocampus, posterior cingulate cortex, and precuneus) and impaired synaptic function over time (Bateman et al. 2012; Dubois et al. 2014). Post-mortem data suggest a temporal pattern of neurofibrillary tangle formation from the transentorhinal layer in early stages of AD proceeding to the entorhinal cortex before subsequent degeneration in the isocortical association areas in later stages of disease progression (Braak and Braak 1991). This focus has led to exploration in clinical trials of anti-A β therapies for AD treatment, which have thus far garnered little success (Karran et al. 2011; Karran and Hardy 2014). AD patients present with heterogeneous symptoms that may be conceptualized as distinct clinical syndromes with relatively greater disturbances in language, visuospatial functions, apraxia, or behavioral manifestations (Stopford et al. 2008). These variations have also been associated with particular clinical biomarkers. For instance, visual perception problems and/or spatial difficulties are often accompanied by posterior cortical atrophy including hypometabolism in these areas as observed by magnetic resonance imaging (MRI) and positron emission tomography (PET) (Graff-Radford et al. 2021; Jack Jr et al. 2019). Furthermore, while genetic variants such as apolipoprotein E4 (ApoE4) have long been known to play a role in development of AD, which is highly heritable (Tanzi 2012), contemporary research is shedding new light on genetic and environmental factors related to AD, such as amyloid precursor protein metabolism (Kunkle et al. 2019) and pesticide exposure (Killin et al. 2016). Below, we review selected aspects of AD biological mechanisms which are potentially relevant to psychedelics’ mechanisms of action.

2.1 Decreased Serotonergic Neurotransmission in AD

Evidence indicates reduced serotonergic neurotransmission in AD may be associated with psychiatric symptoms (Butzlaff and Ponimaskin 2016). Animal models of AD suggest selective neurodegeneration of serotonin pathways and reduced serotonergic neurotransmission (Liu et al. 2008). Preclinical research has shown β -amyloid accumulation leads to a decline in 5-HT_{2A}R levels in the cortex of mice (Holm et al. 2010). In prodromal AD, PET imaging reveals a reduced density of serotonin transporter which is associated with early cognitive changes (Smith et al. 2017). Several studies report decreased 5-HT_{2A}R levels in widespread areas of the brain in AD (Marnier et al. 2012; Mecca 2019). These changes are associated with

neuropsychiatric symptoms including agitation, depression, and psychosis in AD (Chakraborty et al. 2019). Relevant to classic psychedelics, 5-HT_{2A}R density declines in healthy aging throughout the brain and specifically in the hippocampus, and the degree of temporal lobe 5-HT_{2A}R decrease is associated with cognitive decline in AD (Marnier et al. 2012; Versijpt et al. 2003). Some studies point to possible genetic influences of the serotonin system in AD, such as the 5-HT_{2A}R T102C polymorphism, where the CC genotype has been associated with risk of psychotic symptoms in AD (Tang et al. 2017). In human PET studies, neocortical regions including the orbitofrontal cortex (OFC) showed reduced 5-HT_{2A}R binding in both Mild cognitive impairment (MCI) and AD patients (Hasselbalch et al. 2008; Lai et al. 2005; Versijpt et al. 2003). In addition to serotonin, other neurotransmitter systems such as norepinephrine (Theofilas et al. 2017) and acetylcholine (Grothe et al. 2012) have been implicated in AD pathology and identified as targets for AD pharmacotherapies (Marucci et al. 2021). However, the current review focuses primarily on serotonergic neurotransmission due to its key role in psychedelics' biological mechanisms (Nichols 2016),

2.2 *Loss of Synaptic Function in AD*

Data suggest the loss of synaptic function in AD prior to neuronal loss (Selkoe 2002). For example, synaptophysin (a characteristic marker of synaptic integrity) is decreased in prodromal AD (Masliah et al. 2001; Sze et al. 1997; Yuki et al. 2014). One well-validated marker of synaptic density is synaptic vesicle glycoprotein 2 (SV2) which is expressed in virtually all synapses and is located in synaptic vesicles at presynaptic terminals (Mecca 2019). A PET tracer for imaging SV2 density in vivo is now available ([¹¹C]UCB-J) and has demonstrated decreased SV2 density in the hippocampus of patients with AD compared to cognitively unimpaired older adults (Chen et al. 2018).

2.3 *Key Signaling Pathways in AD*

Brain-derived neurotrophic factor (BDNF), a protein critical to neuronal growth and survival, is affected by the accumulation of A β protein in prodromal AD (Peng et al. 2005). This accumulation interferes with the conversion of proBDNF to BDNF such that parietal cortex levels of both proBDNF and BDNF are reduced in prodromal AD and MCI, correlating with cognitive decline (Peng et al. 2005; Tanila 2017). In addition, decreased Tropomyosin receptor kinase B (TrkB) BDNF receptor expression and increased expression of TrkB.T1 (a primary inhibitor of TrkB) result in further BDNF inhibition as well as the prevention of long-term potentiation (LTP) and long-term depression (Eide et al. 1996; Michaelsen et al. 2010) – processes essential to memory formation (Minichiello 2009). The steady decrease of BDNF

and its action, which may occur as a direct result of A β deposition, could be a critical link between the prodromal phase of AD and the beginning of neurodegeneration and cognitive decline, eventually culminating in dementia (Arancibia et al. 2008; Ciaramella et al. 2013).

The Mammalian Target of Rapamycin (mTOR) signaling pathway also has a role in LTP and memory formation (Cammalleri et al. 2003; Hoeffler and Klann 2010). Hyperactivation of mTOR complex I leads to downstream inhibition of cell autophagy, which could result in further A β deposition and tau hyperphosphorylation (Caccamo et al. 2013). Conversely, the activated mTOR signaling pathway has also been shown to induce structural plasticity and neurogenesis by regulating the behavior of axonal growth cones, dendrite arborization, and dendritic spine morphology via control of local protein synthesis (Jaworski and Sheng 2006). Targeting mTOR signaling in key cognitive brain regions could help delay or even prevent cognitive decline during the neurodegeneration phase of AD (Tramutola et al. 2017).

2.4 *Inflammation in AD*

Accumulating evidence has implicated neuroinflammation in the progression of AD (Kinney et al. 2018; Zotova et al. 2010). In post-mortem studies, brain tissue of patients with AD exhibits signs of persisting inflammatory activity, such as activated microglia and astrocyte clusters (Serrano-Pozo et al. 2011b). These in turn release proinflammatory cytokines and interleukins (e.g., interleukin [IL]-1 β , IL-6, and tumor necrosis factor- α [TNF- α]), which cause tissue damage with prolonged exposure, and interact with accumulating A β and NFT to contribute to neuronal loss (Garwood et al. 2011; Wang et al. 2015). Early patient data suggested use of medications such as Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) may be associated with reduced severity of AD symptoms (Rich et al. 1995) and reduced risk of developing AD (Stewart et al. 1997). To date, clinical trials of NSAIDs as a treatment for AD have not shown positive results (Miguel-Álvarez et al. 2015). However, targeted strategies for modulating neuroinflammation remain a viable pathway for developing novel AD therapeutics that continue to be explored (Ozben and Ozben 2019).

2.5 *Changes in Brain Metabolism and Functional Connectivity in AD*

In addition to cellular and molecular mechanisms, human neuroimaging and post-mortem studies provide insight into the neurobiology of AD. PET is a critical tool for understanding and diagnosing AD, allowing A β and tau deposition to be evaluated

in vivo (Brier et al. 2016), and using ligands such as fluorodeoxyglucose (FDG) to assess functional brain metabolism (Rice and Bisdas 2017). These methods have demonstrated differential patterns of atrophy, hypometabolism, and A β and tau aggregation across the course of disease progression, informing the neurodegenerative processes underlying AD (Joie et al. 2012; Ossenkoppele et al. 2016). Current imaging data suggest early-stage AD is marked by A β deposition, atrophy, and metabolic dysfunction in posterior cortical regions, which are active during memory retrieval in healthy individuals (Buckner et al. 2005). As cognitive function declines, concurrent increases in tau deposition are observed in the temporal lobe (Brier et al. 2016) and other key domain-specific regions (e.g., occipital cortex for individuals with visual impairment) (Ossenkoppele et al. 2016).

Functional MRI data also show notable decrease in connectivity in normal aging across several brain networks, while AD mainly shows alterations in the default mode network (DMN), dorsal attention network (DAN), and the precuneus (Hafkemeijer et al. 2012; Klaassens et al. 2017; Tomasi and Volkow 2012). The DMN is primarily composed of the medial prefrontal cortex (mPFC), posterior cingulate cortex (PCC), precuneus, and angular gyrus, which are involved in episodic memory retrieval (Sestieri et al. 2011), a function known to deteriorate in older adults with AD (Mevel et al. 2011; Weintraub et al. 2012). In some cases of AD, DMN desynchronization has been posited to contribute to cognitive decline, consistent with evidence that differences in DMN activation in the precuneus and PCC predicted lower Mini-Mental State Exam (MMSE) scores, typically indicative of more severe dementia (Schwindt et al. 2013). Amyloid accumulation may also affect DMN function, for instance leading to hypoconnectivity within the DMN in early AD (Buckner et al. 2005; Palmqvist et al. 2017). The salience network (SN) has also shown reduced gray matter volume and altered functional connectivity in AD that were associated with neuropsychiatric symptoms (Balthazar et al. 2014), as well as cognitive impairment (He et al. 2014). It has been hypothesized that increased SN connectivity in AD is associated with greater “emotionality” which might contribute to the expression of affective and other neuropsychiatric symptoms (Zhou and Seeley 2014). Lasting alterations in brain network connectivity have been observed after a single dose of psilocybin (Barrett et al. 2020a) and are correlated with psilocybin's antidepressant effects (Carhart-Harris et al. 2017), indicating a potential biological mechanism by which psychedelics could affect AD progression and related symptoms. Notably, the medial temporal lobes have been found to show increases in activation during MCI and early-stage AD, which may be associated with local tau formation and subsequent neurodegeneration and hypoactivation in these regions that then spreads as AD progresses (Pasquini et al. 2019; Putcha et al. 2011).

2.6 Neuropsychiatric Comorbidities in AD

Patients with AD have a high prevalence of comorbid neuropsychiatric symptoms, with more than 40% exhibiting clinically significant symptoms of depression (Lyketsos et al. 2002; Zhao et al. 2016). Beyond other challenges posed by AD, depression adversely impacts both patient and caregiver quality of life (Karttunen et al. 2011; Shin et al. 2005). Moreover, depression is known to mediate the progression of AD, with more pronounced symptoms being associated with greater risk of cognitive decline (Dotson et al. 2010; Herbert and Lucassen 2016; Ruthirakuhan et al. 2019). Typical antidepressant medications have not shown clear evidence of efficacy in patients with dementia, indicating a need for novel treatments (Banerjee et al. 2013; Nelson and Devanand 2011; Rosenberg et al. 2010). Neuropsychiatric symptoms are frequently the first symptoms of prodromal dementia (Leoutsakos et al. 2015) and associated with early manifestations of AD biomarkers (Banning et al. 2021), which has led to the concept of Mild Behavioral Impairment defining five domains of such symptoms which are predictive of incident MCI and dementia (Ismail et al. 2017).

The symptoms of AD also extend beyond cognitive complaints to include highly prevalent, comorbid neuropsychiatric symptoms such as agitation, apathy, sleep disturbances, and anxiety (Lyketsos et al. 2002; Steinberg et al. 2008). These symptoms contribute to disability, worse life quality, impaired activities of daily living, caregiver burden, institutionalization, and accelerated mortality (Lanctôt et al. 2017; Lyketsos et al. 2011; Peters et al. 2015; Soto et al. 2015). While practice guidelines consistently refer to managing such symptoms as central to treating AD (Lyketsos et al. 2006), there are no established effective treatments, highlighting this as an important area for further research into novel therapies. In particular, depressed mood, anxiety, apathy, and reduced quality of life represent compelling targets for brief interventions involving moderate to high-dose psychedelic administration based on existing clinical research described in more detail below. Conversely, other neuropsychiatric symptoms related to AD such as delusions and hallucinations are generally considered contraindications for high-dose psychedelic treatments (Johnson et al. 2008), and it remains unclear how symptoms such as motor disturbances may be influenced by psychedelics.

3 Neurobiology of Psychedelics

A growing body of research supports the administration of 5-HT_{2A}R agonist classic psychedelics such as psilocybin and LSD as a potential treatment for various conditions, including anxiety, mood, and substance use disorders (Garcia-Romeu et al. 2016; Reiff et al. 2020). These compounds represent a novel frontier in the field of psychiatry as possibly transdiagnostic pharmacotherapies with low toxicity and addiction risk, and the potential for long-lasting benefits (Johnson et al. 2018). The

underlying neurobiological mechanisms responsible for these effects are now being explored in basic translational and clinical research, indicating additional potential for these substances as possible novel treatment options for patients with AD.

3.1 Data on the Role of 5-HT_{2A}R in Learning and Memory

Evidence indicates that serotonin has a key modulatory role in learning alongside other neurotransmitters such as dopamine (Aznar and Hervig 2016; Frick et al. 2015; Harvey et al. 2004). In particular, 5-HT_{2A}R agonists like psilocybin have long been studied as potential modulators of learning and memory with early experiments identifying pretreatment with 25ug/kg LSD as a facilitator of reversal learning in rats compared to placebo (King et al. 1972). More recently, administration of a selective 5-HT_{2A}R antagonist was shown to dose-dependently impair spatial reversal learning and increase perseverative errors in rats, further implicating 5-HT_{2A}R signaling in cognitive flexibility processes (Boulougouris et al. 2008). Similarly, reversal learning deficits in chronically stressed rats can be alleviated with chronic SSRI treatment, and this improvement is blocked by injection of a 5-HT_{2A}R antagonist (Furr et al. 2012).

Additionally, LSD injections in the hippocampus have been shown to accelerate classical conditioning of the eyeblink response in rabbits, with chronic LSD injections desensitizing 5-HT_{2A}R but not 5-HT_{2C}R-mediated behavioral responses (Romano et al. 2010). Related work found that chronic treatment of rabbits with an inverse 5-HT_{2A}R agonist increased 5-HT_{2A}R density in the frontal cortex and produced similar acceleration in classical conditioning (Harvey et al. 2004). The extinction of fear memories in rats can be accelerated by administration of 5-HT_{2A}R agonist (4-Bromo-3,6-dimethoxybenzocyclobuten-1-yl)methylamine hydrobromide (TCB-2) and delayed by administration of a 5-HT_{2A}R antagonist (Zhang et al. 2013). Low doses of psilocybin likewise facilitate the extinction of fear memories and may increase hippocampal neurogenesis in rats (Catlow et al. 2013). Furthermore, the spatial tuning of neurons in the prefrontal cortex of rhesus monkeys performing a visual working memory task can be accentuated or attenuated by the delivery of a 5-HT_{2A}R agonist or antagonist, respectively (Williams et al. 2002). The 5-HT_{2A}R agonist TCB-2 can also improve the working memory of rats with medial forebrain bundle lesions intended to mimic the cognitive effects of Parkinson's Disease (Li et al. 2015). Hippocampal TCB-2 injection during memory consolidation enhances the object memory of mice, and this effect is blocked by pretreatment with a 5-HT_{2A}R antagonist, further supporting a key role for 5-HT_{2A}R in modulating memory (Zhang et al. 2016).

In addition to animal studies, research in humans has suggested a role for 5-HT_{2A}R in regulating mood and memory functions. Genetic research has found that variations of 5-HT_{2A}R can influence memory task performance in humans, with carriers of the heterozygous 5-HT_{2A} H452Y polymorphism making more errors during memory tasks (de Quervain et al. 2003), and displaying less right anterior

hippocampal activation in response to novel stimuli compared to their homozygous counterparts (Schott et al. 2011). These data suggest a robust influence of 5-HT_{2A}R activation in diverse learning and memory processes that are relevant to AD (Zhang and Stackman Jr 2015), raising the possibility that low- or high-dose psychedelic administration may have cognition-enhancing effects in patients with AD. Approaches testing low-dose psychedelics might use a chronic dosing regimen every few days over the course of several weeks to assess pre- and post-treatment performance on validated measures of episodic memory, working memory, visuo-spatial processing, and executive function (e.g., Mini-Mental State Exam, Hopkins Verbal Learning Test, Trail Making Test, Raven’s Progressive Matrices, Category Fluency). A similar design could be employed to examine effects of one or more high-dose psychedelic sessions with psychological support, preferably with patients in earlier stages of AD, where there would be less ethical concerns about informed consent regarding study procedures (Kim 2011). Should any signal of cognitive-enhancing effects emerge in initial research, this would pave the way for further study of biological mechanisms using neuroimaging and other biomarker assessment.

3.2 Psychoplastic Effects of Psychedelics and Related Signaling Pathways

Data from cellular and molecular models additionally suggest classic psychedelics may have potential in treating early-stage AD. A recent study found classic psychedelics to selectively induce structural and functional neuroplasticity in vitro and in vivo in the rat prefrontal cortex at an extent comparable to BDNF, with resulting effects posited as “psychoplastic” (Ly et al. 2018). Psychoplastic compounds are defined to produce a measurable change in neuroplasticity within 24–72 h of a single administration. Measurable changes in plasticity include changes in neurite growth, dendritic branching, dendritic spine density, synapse number, and intrinsic excitability, among others (Olson 2018). Recently published data consistent with psychoplastic effects found a single dose of psilocybin led to significant, rapid increases in the formation, size, and density of dendritic spines in mouse medial frontal cortex occurring within 24 h of dosing, with structural changes persisting up to a month later (Shao et al. 2021). Psilocybin was also found to increase excitatory postsynaptic current frequency and to reduce behavioral signs of learned helplessness in a prolonged stress paradigm in mice (Shao et al. 2021). Psychedelics are thought to induce such psychoplastic effects via 5-HT_{2A}R receptor stimulation, which upregulates Ania gene expression and affects glutamatergic function (Nichols and Sanders-Bush 2002). Specifically, this activity amplifies α -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) glutamate receptor signaling, resulting in downstream activation of the mTOR pathway – one of the proposed mechanisms for the neural plasticity – promoting effects of

psychoplastogens (Cavalleri et al. 2018). Recent data indicate that 5-HT_{2A}R stimulation may impact BDNF (Hutten et al. 2021; Tsybko et al. 2020), and result in upregulated activity-regulated cytoskeleton-associated (Arc) protein expression thought to be involved in cytoskeletal rearrangements for synaptic plasticity (Nichols et al. 2003; Nichols and Sanders-Bush 2002).

Additional preclinical research provides further evidence on relevant mechanisms for classic psychedelics to positively impact biological pathways relevant to AD. In rats, a single LSD administration has been shown to increase expression of immediate early genes (IEGs) implicated in synaptic plasticity in various brain regions including the PFC, midbrain, and hippocampus (Nichols et al. 2003; Nichols and Sanders-Bush 2002). Similarly, psilocybin and other 5-HT_{2A}R agonists can induce IEG expression in the mouse cortex (González-Maeso et al. 2007). Psilocybin has also shown dose-dependent and differential alterations in transcriptional regulation in the PFC and hippocampus across multiple plasticity-related genes in rats (Jefsen et al. 2021). Additionally, preliminary data indicate a single administration of the psychedelic 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) can increase dendritic structural density and plasticity in the PFC, enhance fear extinction, and enhance LTP in mice (Revenge et al. 2021). These effects were mediated by 5-HT_{2A}R as evidenced by lack of such effects in 5-HT_{2A}R knockout mice. Furthermore, DOI induced lasting changes up to a week post-drug administration in frontal cortex gene expression in mice further suggesting transcriptional and epigenetic mechanisms may mediate lasting effects of serotonergic psychedelics (Revenge et al. 2021). Chronic administration of DOI and other 5-HT_{2A}R agonists produced increased proBDNF levels and downregulation of TrkB receptors in mice (Tsybko et al. 2020). Furthermore, the psychedelic 5-MeO-DMT has also been shown to induce neuroplastic changes after a single dose including increased cell growth and maturation in the dentate gyrus of mice (Lima da Cruz et al. 2018).

Finally, a series of recent studies conducted in pigs have also shown lasting changes in PFC gene expression up to a week after a single dose of psilocybin (Donovan et al. 2021). Increased hippocampal synaptic vesicle protein 2A (SV2A) density and decreased hippocampal and PFC 5-HT_{2A}R density have been found 24 h post-psilocybin administration, and significant, ongoing increases in SV2A density have been detected at 1 week post-psilocybin administration (Raval et al. 2021). SV2A protein levels are thought to reflect presynaptic density, suggesting psilocybin may increase synaptogenesis up to a week after a single psilocybin exposure in pigs (Raval et al. 2021). Furthermore, novel evidence suggests 5-HT_{2A}R inverse agonist administration quickly and significantly reduced brain A β levels and improved cognitive function in a mouse model of AD, though this effect was not observed in 5-HT_{2A}R knockout mice (Yuede et al. 2021). Taken together, this preclinical evidence suggests classic psychedelics may act via a host of 5-HT_{2A}R mediated biological mechanisms to promote rapid changes in genetic expression leading to longer lasting functional and structural brain changes, which may in turn be associated with therapeutic effects observed in human trials (Fig. 1). Although it remains to be seen whether the mechanisms described here lead to clinical improvement in humans, preclinical data on 5-HT_{2A}R agonist effects on learning and memory,




Fig. 1 A diagram of three converging pathways that may be responsible for induced neural plasticity, potentially resulting in lasting beneficial effects following psychedelic administration: 5-HT_{2A}R upregulation of neocortical BDNF, amplification of AMPA receptor activity resulting in downstream activation of mTOR, and upregulated Arc protein expression

combined with the observed neurological, antidepressant, and anxiolytic effects of psychedelics discussed below, present a compelling rationale for targeted investigation of 5-HT_{2A}R agonist effects in patients with AD. Psychoplastogenic effects could present a potential mechanism to slow or reverse atrophy in key brain regions affected by AD and could be studied after chronic low-dose or one or more high-dose psychedelic administration sessions in AD patients using pre- and post-neuroimaging and neuropsychological testing, parallel to research in healthy volunteers described in more detail below (Madsen et al. 2020). Similarly, preclinical findings on 5-HT_{2A}R mediated reductions in A β levels (Yuede et al. 2021) could be studied in clinical trials administering classic psychedelics to early-stage AD patients and assessing longitudinal impact on A β , cognitive function, and disease progression, providing another possible, complementary therapeutic mechanism for advancing AD treatment.

3.3 Psychedelics as Anti-inflammatory Agents

Preclinical studies have shown robust anti-inflammatory effects of classic psychedelics (Flanagan and Nichols 2018). The 5-HT_{2A}R agonist psychedelics (R)-2,4-dimethoxy-4-iodoamphetamine [(R)-DOI] and LSD (among others) have been found to suppress TNF- α induced inflammation in rat aortic smooth muscle cells, with (R)-DOI exhibiting substantial potency in this regard (Yu et al. 2008). These effects were consistent in vivo in mice, showing anti-inflammatory effects of (R)-DOI in aorta, small intestine, and blood at low-dose levels, which were blocked by co-administration of a selective 5-HT_{2A}R antagonist, indicating a central role for 5-HT_{2A}R in anti-inflammatory effects (Nau Jr et al. 2013). In addition to 5-HT_{2A}R mediated anti-inflammatory effects, cellular models suggest some classic psychedelics such as DMT and 5-MeO-DMT may exert additional anti-inflammatory effects via the Sigma-1 receptor, including inhibition of IL-1 β , IL-6, and TNF- α (Szabo et al. 2014), proinflammatory cytokines known to be involved in AD pathology (Wang et al. 2015). Furthermore, a recent study demonstrated the DMT containing admixture ayahuasca, but not placebo, significantly reduced levels of the inflammatory biomarker C-reactive protein from pre- to 48 h-post administration, and these reductions were correlated with mood improvements in patients with treatment-resistant depression (Galvão-Coelho et al. 2020). Anti-inflammatory effects of psychedelics have not yet been conclusively studied in human clinical populations but may be observed after repeated low doses of psychedelics or single high doses. Such effects could be studied in AD patients via prospective measurement of cytokines and related inflammatory biomarkers that may also serve as a therapeutic target for treatment during early-stage AD or possibly in later stages using chronic low-dose regimens.

3.4 *Psychedelics' Effects in Humans*

Recent imaging data provide insight into the activity of the brain during and after acute psychedelic effects. Resting state network connectivity during psilocybin peak effects shows increased between-network functional connectivity and simultaneous decreased within-network connectivity in the DMN, visual networks, and auditory networks (Mason et al. 2020). This altered network connectivity may be due in part to psilocybin's ability to reduce overall activity in both sides of the claustrum, a key structure in the executive control of behavior, while simultaneously modifying the connectivity of the claustrum with different networks such as the frontoparietal task network (Barrett et al. 2020b). These acute effects are time-dependent and may be predicted by baseline global brain connectivity (Preller et al. 2020).

Psilocybin also may mediate glutamate concentration in areas like the hippocampus and medial prefrontal cortex via 5-HT_{2A}R, ultimately leading to the activation of AMPA receptors and the increased expression of BDNF (Hutten et al. 2021; Mason et al. 2020). During acute psilocybin effects, working memory may appear unchanged or impaired, perhaps due to attentional deficits stemming from an impaired ability to ignore irrelevant stimuli (Barrett et al. 2018; Carter et al. 2005). However, although the acute subjective effects of psilocybin last a matter of hours, fMRI research has found longer term effects in the brain such as decreased amygdala response during affective processing tasks a week after administration and increased global functional brain connectivity a full month after administration (Barrett et al. 2020a). Such long-term effects suggest that psilocybin may induce a period of heightened neuroplasticity lasting weeks after initial psilocybin administration.

Volunteers with treatment-resistant depression were found to have decreased amygdala cerebral blood flow and increased DMN integrity 1 day after psilocybin administration, which has been proposed as a potential “reset” mechanism of psychedelics in which networks like the DMN may experience “modular disintegration” acutely and then “re-integration” afterwards associated with therapeutic outcomes (Carhart-Harris et al. 2017). Post-acute changes in functional connectivity have also been found in healthy volunteers 1 day after administration of the classic psychedelic admixture ayahuasca, including increased connectivity within the salience network, decreased connectivity within the DMN, and greater connectivity between the salience network and DMN, with the latter showing association with acute affective changes (Pasquini et al. 2020). Although these findings are not completely consistent with prior post-acute functional connectivity data on psilocybin in depressed patients (Carhart-Harris et al. 2017), they do represent a relevant area for further study using psychedelics and functional neuroimaging in patients with AD, who have shown differential patterns of connectivity alterations related to neuropsychiatric symptoms (Balthazar et al. 2014).

Memory Effects Human studies of psychedelics' effects on memory have largely focused on performance during drug effects, with most finding acute, dose-dependent impairment under the influence of moderate or high doses of psychedelics such as psilocybin (Barrett et al. 2018), LSD (Jarvik et al. 1955; Pokorny et al.

2020), and ayahuasca (Bouso et al. 2013) on various memory and cognitive tasks (Healy 2021). These impairments have been demonstrated across a number of domains such as working memory (Bouso et al. 2013; Wittmann et al. 2007) and word recall (Barrett et al. 2018). However, acute changes in autobiographical memory during psychedelic effects have also been reported, suggesting LSD (Langs 1967) and psilocybin (Carhart-Harris et al. 2012) can facilitate recall and vividness of salient life memories, a potentially relevant mechanism for treatment of AD, which is known to entail episodic memory impairment (Tromp et al. 2015). If psychedelic administration has any long-term effects on human memory, data on persisting brain and mood effects (e.g., Barrett et al. 2020a) suggest that they may not resemble acute effects. However, post-acute effects of psychedelics on cognition and memory in clinical populations have yet to be rigorously studied.

Reducing Depression, Anxiety, and Existential Distress A major focus of recent research has been examining classic psychedelics' effects on mood and anxiety symptoms. Revisiting promising work from the earlier era of research on psychedelics (Grof et al. 1973; Richards et al. 1977), recent double-blind, controlled studies found a single moderate dose of the classic psychedelic psilocybin to produce clinically significant antidepressant effects and reduced anxiety in patients with life-threatening cancer diagnoses (Griffiths et al. 2016; Grob et al. 2011; Ross et al. 2016). In the largest of these contemporary trials, 51 cancer patients were administered a moderate to high dose of psilocybin under supportive conditions, with a majority showing therapeutic reductions in depression and anxiety and improved quality of life that persisted for 6 months (Griffiths et al. 2016). Additional pilot studies have found persisting anxiolytic effects of high-dose LSD treatment in patients with life-threatening illness (Gasser et al. 2014), as well as rapid, sustained antidepressant effects of psilocybin in patients with treatment-resistant major depression lasting 3 months (Carhart-Harris et al. 2016), and rapid antidepressant effects of ayahuasca lasting at least 7 days (Palhano-Fontes et al. 2019). Recent controlled trials have provided further support for antidepressant effects of psilocybin (Carhart-Harris et al. 2021; Davis et al. 2021).

One study of psilocybin in 27 individuals with major depression used a wait-list controlled design, randomizing participants to either an immediate treatment condition in which they received a moderate (20 mg/70 kg) and high (30 mg/70 kg) dose of psilocybin approximately 2 weeks apart with psychological support throughout, or to a control condition in which participants began an identical treatment after an 8-week delay period during which their mood was monitored. Twenty-four individuals completed the study, showing significantly greater decreases in GRID-Hamilton Depression Rating Scale (GRID-HAMD) scores in the immediate treatment group at 1 and 4 weeks after the second psilocybin session compared to the wait-list control group at corresponding timepoints (Davis et al. 2021). After receiving the psilocybin intervention, the wait-list control group also showed statistically significant decreases from baseline in GRID-HAMD and other depression and anxiety measures lasting 4 weeks after the second psilocybin session, with more than half the

sample overall (54%) meeting criteria for remission of depression at 4 weeks post-treatment.

Another study used a double-blind, randomized comparative efficacy design to assess effects of two high doses (25 mg) of psilocybin approximately 3 weeks apart compared with 6 weeks of daily oral escitalopram, an approved selective serotonin reuptake inhibitor (SSRI) antidepressant medication in a sample of 59 participants with moderate to severe major depression (Carhart-Harris et al. 2021). Results found significant reductions in depressive symptoms in both groups, with participants who received psilocybin showing greater improvements overall. Although these improvements did not meet statistical significance for superiority of psilocybin in the primary outcome (i.e., Quick Inventory of Depressive Symptomatology-Self-Report), depression remission was found in 57% of participants in the psilocybin condition at the 6 week timepoint compared with 28% in the escitalopram condition, and secondary outcome measures also favored psilocybin, indicating two high doses of psilocybin are at least as effective – if not more so – in treating depression than 6 weeks of daily escitalopram.

Increased Wellbeing and Life Satisfaction A growing body of work has shown sustained well-being benefits after classic psychedelic administration across diverse samples, from healthy volunteers (Griffiths et al. 2008, 2018) and older long-term AIDS survivors (Anderson et al. 2020) to people with a range of health conditions including cancer-related distress (Agin-Liebman et al. 2020; Swift et al. 2017), alcohol dependence (Bogenschutz et al. 2018), nicotine dependence (Noorani et al. 2018), and major depression (Watts et al. 2017). In many cases, such persisting effects are correlated with enduring personality changes such as increased openness, as well as increased life satisfaction and overall well-being (Erritzoe et al. 2018; Griffiths et al. 2008; MacLean et al. 2011; Madsen et al. 2020; Schmid and Liechti 2018; Smigielski et al. 2019a). Although the mechanisms for post-acute alterations in personality, behavior, and well-being are still under investigation, they have been linked to acute psychoactive drug effects that include a sense of insight and meaning (Erritzoe et al. 2018; Griffiths et al. 2008; Smigielski et al. 2019a), spiritual or mystical-type effects characterized by a sense of oneness (Garcia-Romeu et al. 2014; MacLean et al. 2011; Schmid and Liechti 2018), and changes in 5-HT_{2A}R binding (Madsen et al. 2020) and brain network functional connectivity (Barrett et al. 2020a; Sampedro et al. 2017; Smigielski et al. 2019b). That classic psychedelics have shown these persisting benefits across such a wide range of individuals provides good impetus to study them in patients with AD who are known to suffer from substantial decrements to quality of life overall (Karttunen et al. 2011; Shin et al. 2005).

4 Rationale and Approaches for Researching Psychedelics in Patients with AD

The data presented above provide good evidence that for some patients with AD, classic psychedelics may provide potential therapeutic benefits worth exploring further. To this end, we are currently conducting a pilot study to examine the potential of psilocybin to treat neuropsychiatric symptoms (NPS) in patients with early-stage AD and MCI. The trial is the first to our knowledge using moderate (15 mg/70 kg) and high-dose (25 mg/70 kg) psilocybin in patients with early-stage AD or MCI and depressed mood (ClinicalTrials.gov NCT04123314). Because of potential risks in more advanced cases of AD which may include symptoms such as delusions or hallucinations that could be exacerbated by high-dose psychedelic administration (Scarmeas et al. 2005), this research is geared toward earlier phases of the disease, consistent with recommendations that “the field should explore whether the long prodromal phase of AD creates novel possibilities to maintain cellular functionality and brain homeostasis to postpone the phase of irreparable damage and decay” (Sala Frigerio and De Strooper 2016, p. 71).

Clinical research to date has found benefits related largely to higher dose administration of classic psychedelics (Anderson et al. 2020; Bogenschutz et al. 2015; Carhart-Harris et al. 2021; Davis et al. 2021; Griffiths et al. 2016; Johnson et al. 2014). These data also suggest mood, quality of life, and general well-being improvements associated with high-dose psychedelic administration as potential therapeutic targets for patients with AD. Other approaches may consider use of lower repeated dosing of classic psychedelics in this population (Family et al. 2020). Currently available data on psychedelic microdosing (using chronic sub-perceptual doses that are not profoundly psychoactive) have failed to demonstrate consistent benefits in controlled trials (Bershad et al. 2019; Family et al. 2020; Hutten et al. 2020). However, this area remains open for further investigation to expand our understanding of the possible benefits, risks, and mechanisms of psychedelic treatments in AD. Additionally, the potential of classic psychedelics to treat other neurodegenerative disorders represents another compelling direction for future research.

5 Conclusion

Classic psychedelics with psychoplastogenic properties have the potential to be a powerful tool in the treatment of early-stage AD or MCI. Their ability to encourage neuronal growth similar to BDNF, a key protein that MCI patients produce at reduced levels, could possibly slow or even reverse the effects of a disease characterized by neurodegeneration. Agents that selectively induce neural plasticity in the cerebral cortex via direct action on 5-HT_{2A}R, which are highly expressed in layer 5 pyramidal neurons of the cortex, represent an as yet uninvestigated

pharmacological class in patients with AD. In sum, three converging biological pathways may be responsible for induced neural plasticity resulting in long-lasting and profound effects following psychedelic administration: 5-HT_{2A}R upregulation of neocortical BDNF, amplification of AMPA receptor activity resulting in downstream activation of mTOR, and upregulated Arc protein expression (Fig. 1). These plasticity-promoting pathways could represent a novel disease modifying treatment approach to treat AD that selectively induces neural plasticity in key cognitive brain regions like the prefrontal cortex, that as a result of the disease are deficient in endogenous plasticity-promoting compounds like BDNF. In addition, classic psychedelics' antidepressant and anxiolytic effects could provide important inroads for promoting psychological benefits in patients struggling with AD and neuropsychiatric comorbidities such as depression and apathy.

Questions remain as to the primary therapeutic mechanisms underlying psychedelic-assisted treatments. Some propose that characteristic mystical-type or ego-dissolving subjective effects of high-dose psychedelics are necessary for psychological benefits, (Yaden and Griffiths 2021) and others posit purely biological mechanisms as necessary and sufficient to achieve lasting positive effects (Olson 2021). It is our contention that there may be truth to both. Neuroplasticity inducing and anti-inflammatory properties of classic psychedelics suggest the potential for purely biological therapeutic activity across several mechanisms, even at doses that would not produce strong psychoactive effects (Flanagan and Nichols 2018; Ly et al. 2018; Shao et al. 2021). Thus, low-dose psychedelic treatments could have specific applications that may not necessitate subjective effects, such as reducing brain atrophy in neurodegenerative conditions, or recent work showing persisting reductions in migraine after a single dose of psilocybin that were not associated with psychoactive effects (Schindler et al. 2021). However, for particular conditions like depression, anxiety, addictions, and existential distress, current evidence suggests the subjective effects of classic psychedelics play a pivotal role, likely driven by their ability to alter core cognitive, emotional, and self-referential processes that can facilitate therapeutic insight, catharsis, and behavior change (Garcia-Romeu et al. 2014; Griffiths et al. 2016; MacLean et al. 2011; Roseman et al. 2018). As such, we recommend continued research of both low- and high-dose psychedelic therapy approaches and to tailor treatments according to clinical target and population.

The present discussion aims to inform the nascent field of clinical psychedelic research in patients with AD (George and Hanson 2019; Vann Jones and O'Kelly 2020). The data presented here, along with ongoing pilot research, set the stage to examine psychedelic treatments as potential avenues to affect disease progression and to enhance well-being and quality of life for patients with AD. We believe this work is both timely and promising, and represents a viable path forward for development of novel therapeutics in AD.

Acknowledgements The authors would like to thank Matthew W. Johnson, Ph.D., Roland R. Griffiths, Ph.D., Frederick S. Barrett, Ph.D., William A. Richards, Ph.D., Mary Cosimano, M.S.W., Annie Umbricht, M.D., and Natalie Gukasyan, M.D. for their support in this work.

Declaration of Interest AGR serves as a scientific advisor to ETHA Natural Botanicals and NeonMind Biosciences.

Funding/Support Funding for this research was provided by the Pineapple Fund, CSP Fund, Heffter Research Institute, and by Tim Ferriss, Matt Mullenweg, Blake Mycoskie, Craig Nerenberg, and the Steven and Alexandra Cohen Foundation.

References

- Agin-Liebess GI, Malone T, Yalch MM, Mennenga SE, Ponté KL, Guss J, Bossis AP, Grigsby J, Fischer S, Ross S (2020) Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer. *J Psychopharmacol* 34 (2):155–166
- Alzheimer's Association (2021) Alzheimer's disease facts and figures. *Alzheimers Dement* 17 (3):327–406. <https://doi.org/10.1002/alz.12328>
- Anderson BT, Danforth A, Daroff PR, Stauffer C, Ekman E, Agin-Liebess G, Trope A, Boden MT, Dilley PJ, Mitchell J, Woolley J (2020) Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: an open-label safety and feasibility pilot study. *EClinicalMedicine* 27. <https://doi.org/10.1016/j.eclinm.2020.100538>
- Arancibia S, Silhol M, Moulrière F, Meffre J, Höllinger I, Maurice T, Tapia-Arancibia L (2008) Protective effect of BDNF against beta-amyloid induced neurotoxicity in vitro and in vivo in rats. *Neurobiol Dis* 31(3):316–326. <https://doi.org/10.1016/j.nbd.2008.05.012>
- Ayton S (2021) Brain volume loss due to donanemab. *Eur J Neurol* 28(9):e67–e68. <https://doi.org/10.1111/ene.15007>
- Aznar S, Hervig ME-S (2016) The 5-HT_{2A} serotonin receptor in executive function: implications for neuropsychiatric and neurodegenerative diseases. *Neurosci Biobehav Rev* 64:63–82. <https://doi.org/10.1016/j.neubiorev.2016.02.008>
- Balthazar MLF, Pereira FRS, Lopes TM, da Silva EL, Coan AC, Campos BM, Duncan NW, Stella F, Northoff G, Damasceno BP, Cendes F (2014) Neuropsychiatric symptoms in Alzheimer's disease are related to functional connectivity alterations in the salience network. *Hum Brain Mapp* 35(4):1237–1246. <https://doi.org/10.1002/hbm.22248>
- Banerjee S, Hellier J, Romer R, Dewey M, Knapp M, Ballard C, Baldwin R, Bentham P, Fox C, Holmes C, Katona C, Livingston G, Lawton C, McCrae N, Moniz-Cook E, Murray J, Nurock J, Orrell M, O'Brien J et al (2013) Study of the use of antidepressants for depression in dementia: the HTA -SADD trial – a multicentre, randomised, double-blind, placebo-controlled trial of the clinical effectiveness and cost-effectiveness of sertraline and mirtazapine. *Health Technol Assess* 17(7):Article 7. <http://www.hta.ac.uk/research/HTAJournal.shtml>
- Banning LCP, Ramakers IHGB, Rosenberg PB, Lyketsos CG, Leoutsakos J-MS (2021) Alzheimer's disease biomarkers as predictors of trajectories of depression and apathy in cognitively normal individuals, mild cognitive impairment, and Alzheimer's disease dementia. *Int J Geriatr Psychiatry* 36(1):224–234. <https://doi.org/10.1002/gps.5418>
- Barrett FS, Carbonaro TM, Hurwitz E, Johnson MW, Griffiths RR (2018) Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: effects on cognition. *Psychopharmacology* 235(10):2915–2927. <https://doi.org/10.1007/s00213-018-4981-x>
- Barrett FS, Doss MK, Sepeda ND, Pekar JJ, Griffiths RR (2020a) Emotions and brain function are altered up to one month after a single high dose of psilocybin. *Sci Rep* 10(1):1–14. <https://doi.org/10.1038/s41598-020-59282-y>
- Barrett FS, Kimmel SR, Griffiths RR, Seminowicz DA, Mathur BN (2020b) Psilocybin acutely alters the functional connectivity of the claustrum with brain networks that support perception,

- memory, and attention. *NeuroImage* 218:116980. <https://doi.org/10.1016/j.neuroimage.2020.116980>
- Bateman RJ, Xiong C, Benzinger TLS, Fagan AM, Goate A, Fox NC, Marcus DS, Cairns NJ, Xie X, Blazey TM, Holtzman DM, Santacruz A, Buckles V, Oliver A, Moulder K, Aisen PS, Ghetti B, Klunk WE, McDade E et al (2012) Clinical and biomarker changes in dominantly inherited Alzheimer's disease. *N Engl J Med* 367(9):795–804. <https://doi.org/10.1056/NEJMoa1202753>
- Bershad AK, Schepers ST, Bremmer MP, Lee R, de Wit H (2019) Acute subjective and behavioral effects of microdoses of lysergic acid diethylamide in healthy human volunteers. *Biol Psychiatry* 86(10):792–800. <https://doi.org/10.1016/j.biopsych.2019.05.019>
- Bloom GS (2014) Amyloid- β and tau: the trigger and bullet in Alzheimer disease pathogenesis. *JAMA Neurol* 71(4):505–508. <https://doi.org/10.1001/jamaneurol.2013.5847>
- Bogenschutz MP, Forchimes AA, Pommy JA, Wilcox CE, Barbosa PCR, Strassman RJ (2015) Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. *J Psychopharmacol* 29(3):289–299
- Bogenschutz MP, Podrebarac SK, Duane JH, Amegadzie SS, Malone TC, Owens LT, Ross S, Mennenga SE (2018) Clinical interpretations of patient experience in a trial of psilocybin-assisted psychotherapy for alcohol use disorder. *Front Pharmacol* 9. <https://doi.org/10.3389/fphar.2018.00100>
- Boulougouris V, Glennon JC, Robbins TW (2008) Dissociable effects of selective 5-HT 2A and 5-HT 2C receptor antagonists on serial spatial reversal learning in rats. *Neuropsychopharmacology* 33(8):2007–2019. <https://doi.org/10.1038/sj.npp.1301584>
- Bouso JC, Fábregas JM, Antonijoa RM, Rodríguez-Fornells A, Riba J (2013) Acute effects of ayahuasca on neuropsychological performance: differences in executive function between experienced and occasional users. *Psychopharmacology* 230(3):415–424. <https://doi.org/10.1007/s00213-013-3167-9>
- Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. *Acta Neuropathol* 82(4):239–259. <https://doi.org/10.1007/BF00308809>
- Brier MR, Gordon B, Friedrichsen K, McCarthy J, Stern A, Christensen J, Owen C, Aldea P, Su Y, Hassenstab J, Cairns NJ, Holtzman DM, Fagan AM, Morris JC, Benzinger TLS, Ances BM (2016) Tau and A β imaging, CSF measures, and cognition in Alzheimer's disease. *Sci Transl Med* 8(338):338ra66. <https://doi.org/10.1126/scitranslmed.aaf2362>
- Buckner RL, Snyder AZ, Shannon BJ, LaRossa G, Sachs R, Fotenos AF, Sheline YI, Klunk WE, Mathis CA, Morris JC, Mintun MA (2005) Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. *J Neurosci* 25(34):7709–7717. <https://doi.org/10.1523/JNEUROSCI.2177-05.2005>
- Butzlaff M, Ponimaskin E (2016) The role of serotonin receptors in Alzheimer's disease. *Opera Med Physiol* 2(1):77–86
- Caccamo A, Magrì A, Medina DX, Wisely EV, López-Aranda MF, Silva AJ, Oddo S (2013) mTOR regulates tau phosphorylation and degradation: implications for Alzheimer's disease and other tauopathies. *Aging Cell* 12(3):370–380. <https://doi.org/10.1111/accel.12057>
- Cammalleri M, Lütjens R, Berton F, King AR, Simpson C, Francesconi W, Sanna PP (2003) Time-restricted role for dendritic activation of the mTOR-p70S6K pathway in the induction of late-phase long-term potentiation in the CA1. *Proc Natl Acad Sci* 100(24):14368–14373. <https://doi.org/10.1073/pnas.2336098100>
- Carhart-Harris RL, Leech R, Williams TM, Erritzoe D, Abbasi N, Bargiotas T, Hobden P, Sharp DJ, Evans J, Feilding A, Wise RG, Nutt DJ (2012) Implications for psychedelic-assisted psychotherapy: functional magnetic resonance imaging study with psilocybin. *Br J Psychiatry* 200(3):238–244. <https://doi.org/10.1192/bjp.bp.111.103309>
- Carhart-Harris RL, Bolstridge M, Rucker J, Day CMJ, Erritzoe D, Kaelen M, Bloomfield M, Rickard JA, Forbes B, Feilding A, Taylor D, Pilling S, Curran VH, Nutt DJ (2016) Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. *Lancet Psychiatry* 3(7):619–627. [https://doi.org/10.1016/S2215-0366\(16\)30065-7](https://doi.org/10.1016/S2215-0366(16)30065-7)

- Carhart-Harris RL, Roseman L, Bolstridge M, Demetriou L, Pannekoek JN, Wall MB, Tanner M, Kaelen M, McGonigle J, Murphy K, Leech R, Curran HV, Nutt DJ (2017) Psilocybin for treatment-resistant depression: FMRI-measured brain mechanisms. *Sci Rep* 7(1):13187. <https://doi.org/10.1038/s41598-017-13282-7>
- Carhart-Harris R, Giribaldi B, Watts R, Baker-Jones M, Murphy-Beiner A, Murphy R, Martell J, Blemings A, Erritzoe D, Nutt DJ (2021) Trial of psilocybin versus escitalopram for depression. *N Engl J Med* 384(15):1402–1411
- Carter OL, Burr DC, Pettigrew JD, Wallis GM, Hasler F, Vollenweider FX (2005) Using psilocybin to investigate the relationship between attention, working memory, and the serotonin 1A and 2A receptors. *J Cogn Neurosci* 17(10):1497–1508. <https://doi.org/10.1162/089892905774597191>
- Catlow BJ, Song S, Paredes DA, Kirstein CL, Sanchez-Ramos J (2013) Effects of psilocybin on hippocampal neurogenesis and extinction of trace fear conditioning. *Exp Brain Res* 228(4):481–491. <https://doi.org/10.1007/s00221-013-3579-0>
- Cavalleri L, Merlo Pich E, Millan MJ, Chiamulera C, Kunath T, Spano PF, Collo G (2018) Ketamine enhances structural plasticity in mouse mesencephalic and human iPSC-derived dopaminergic neurons via AMPAR-driven BDNF and mTOR signaling. *Mol Psychiatry* 23(4):812–823. <https://doi.org/10.1038/mp.2017.241>
- Chakraborty S, Lennon JC, Malkaram SA, Zeng Y, Fisher DW, Dong H (2019) Serotonergic system, cognition, and BPSD in Alzheimer's disease. *Neurosci Lett* 704:36–44. <https://doi.org/10.1016/j.neulet.2019.03.050>
- Chen M-K, Mecca AP, Naganawa M, Finnema SJ, Toyonaga T, Lin S, Najafzadeh S, Ropchan J, Lu Y, McDonald JW, Michalak HR, Nabulsi NB, Arnsten AFT, Huang Y, Carson RE, van Dyck CH (2018) Assessing synaptic density in Alzheimer disease with synaptic vesicle glycoprotein 2A positron emission tomographic imaging. *JAMA Neurol* 75(10):1215. <https://doi.org/10.1001/jamaneurol.2018.1836>
- Ciamarella A, Salani F, Bizzoni F, Orfei MD, Langella R, Angelucci F, Spalletta G, Taddei AR, Caltagirone C, Bossù P (2013) The stimulation of dendritic cells by amyloid beta 1–42 reduces BDNF production in Alzheimer's disease patients. *Brain Behav Immun* 32:29–32. <https://doi.org/10.1016/j.bbi.2013.04.001>
- Davis AK, Barrett FS, May DG, Cosimano MP, Sepeda ND, Johnson MW, Finan PH, Griffiths RR (2021) Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial. *JAMA Psychiat* 78(5):481–489
- de Quervain DJ-F, Henke K, Aerni A, Coluccia D, Wollmer MA, Hock C, Nitsch RM, Papassotiropoulos A (2003) A functional genetic variation of the 5-HT2a receptor affects human memory. *Nat Neurosci* 6(11):1141–1142. <https://doi.org/10.1038/nn1146>
- Dennis EL, Thompson PM (2014) Functional brain connectivity using fMRI in aging and Alzheimer's disease. *Neuropsychol Rev* 24(1):49–62. <https://doi.org/10.1007/s11065-014-9249-6>
- Doggrell SA (2021) Still grasping at straws: donanemab in Alzheimer's disease. *Expert Opin Investig Drugs* 30(8):797–801. <https://doi.org/10.1080/13543784.2021.1948010>
- Donovan LL, Johansen JV, Ros NF, Jaber E, Linnet K, Johansen SS, Ozenne B, Issazadeh-Navikas S, Hansen HD, Knudsen GM (2021) Effects of a single dose of psilocybin on behaviour, brain 5-HT2A receptor occupancy and gene expression in the pig. *Eur Neuropsychopharmacol* 42:1–11. <https://doi.org/10.1016/j.euroneuro.2020.11.013>
- Dotson VM, Beydoun MA, Zonderman AB (2010) Recurrent depressive symptoms and the incidence of dementia and mild cognitive impairment. *Neurology* 75(1):27–34. <https://doi.org/10.1212/WNL.0b013e3181e62124>
- Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, DeKosky ST, Gauthier S, Selkoe D, Bateman R, Cappa S, Crutch S, Engelborghs S, Frisoni GB, Fox NC, Galasko D, Habert M-O, Jicha GA, Nordberg A et al (2014) Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. *Lancet Neurol* 13(6):614–629. [https://doi.org/10.1016/S1474-4422\(14\)70090-0](https://doi.org/10.1016/S1474-4422(14)70090-0)

- Eide FF, Vining ER, Eide BL, Zang K, Wang X-Y, Reichardt LF (1996) Naturally occurring truncated trkB receptors have dominant inhibitory effects on brain-derived neurotrophic factor signaling. *J Neurosci* 16(10):3123–3129. <https://doi.org/10.1523/JNEUROSCI.16-10-03123.1996>
- Erritzoe D, Roseman L, Nour MM, MacLean K, Kaelen M, Nutt DJ, Carhart-Harris RL (2018) Effects of psilocybin therapy on personality structure. *Acta Psychiatr Scand* 138(5):368–378. <https://doi.org/10.1111/acps.12904>
- Family N, Maillet EL, Williams LTJ, Krediet E, Carhart-Harris RL, Williams TM, Nichols CD, Goble DJ, Raz S (2020) Safety, tolerability, pharmacokinetics, and pharmacodynamics of low dose lysergic acid diethylamide (LSD) in healthy older volunteers. *Psychopharmacology* 237(3):841–853. <https://doi.org/10.1007/s00213-019-05417-7>
- Flanagan TW, Nichols CD (2018) Psychedelics as anti-inflammatory agents. *Int Rev Psychiatry* 30(4):363–375. <https://doi.org/10.1080/09540261.2018.1481827>
- Frick LR, Bernardez-Vidal M, Hocht C, Zanutto BS, Rapanelli M (2015) Dual role of serotonin in the acquisition and extinction of reward-driven learning: involvement of 5-HT1A, 5-HT2A and 5-HT3 receptors. *Behav Brain Res* 277:193–203. <https://doi.org/10.1016/j.bbr.2014.06.025>
- Furr A, Lapiz-Bluhm MD, Morilak DA (2012) 5-HT2A receptors in the orbitofrontal cortex facilitate reversal learning and contribute to the beneficial cognitive effects of chronic citalopram treatment in rats. *Int J Neuropsychopharmacol* 15(9):1295–1305. <https://doi.org/10.1017/S1461145711001441>
- Galvão-Coelho NL, de Menezes Galvão AC, de Almeida RN, Palhano-Fontes F, Campos Braga I, Lobão Soares B, Maia-de-Oliveira JP, Perkins D, Sarris J, de Araujo DB (2020) Changes in inflammatory biomarkers are related to the antidepressant effects of Ayahuasca. *J Psychopharmacol* 34(10):1125–1133
- García-Romeu A, Griffiths RR, Johnson MW (2014) Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction. *Curr Drug Abuse Rev* 7(3):157–164
- García-Romeu A, Kersgaard B, Addy PH (2016) Clinical applications of hallucinogens: a review. *Exp Clin Psychopharmacol* 24(4):229
- Garwood CJ, Pooler AM, Atherton J, Hanger DP, Noble W (2011) Astrocytes are important mediators of a β -induced neurotoxicity and tau phosphorylation in primary culture. *Cell Death Dis* 2(6):e167–e167
- Gasser P, Holstein D, Michel Y, Doblin R, Yazar-Klosinski B, Passie T, Brenneisen R (2014) Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. *J Nerv Ment Dis* 202(7):513
- George DR, Hanson R (2019) Imagining a role for psychedelics in dementia care. *Am J Geriatr Psychiatry* 27(9):1028–1030. <https://doi.org/10.1016/j.jagp.2019.03.008>
- González-Maeso J, Weisstaub NV, Zhou M, Chan P, Ivic L, Ang R, Lira A, Bradley-Moore M, Ge Y, Zhou Q, Sealfon SC, Gingrich JA (2007) Hallucinogens recruit specific cortical 5-HT2A receptor-mediated signaling pathways to affect behavior. *Neuron* 53(3):439–452. <https://doi.org/10.1016/j.neuron.2007.01.008>
- Graff-Radford J, Yong KXX, Apostolova LG, Bouwman FH, Carrillo M, Dickerson BC, Rabinovici GD, Schott JM, Jones DT, Murray ME (2021) New insights into atypical Alzheimer's disease in the era of biomarkers. *Lancet Neurol* 20(3):222–234. [https://doi.org/10.1016/S1474-4422\(20\)30440-3](https://doi.org/10.1016/S1474-4422(20)30440-3)
- Griffiths RR, Richards WA, Johnson MW, McCann UD, Jesse R (2008) Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. *J Psychopharmacol* 22(6):621–632
- Griffiths RR, Johnson MW, Carducci MA, Umbricht A, Richards WA, Richards BD, Cosimano MP, Klinedinst MA (2016) Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. *J Psychopharmacol* 30(12):1181–1197. <https://doi.org/10.1177/0269881116675513>
- Griffiths RR, Johnson MW, Richards WA, Richards BD, Jesse R, MacLean KA, Barrett FS, Cosimano MP, Klinedinst MA (2018) Psilocybin-occasioned mystical-type experience in

- combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors. *J Psychopharmacol* 32(1):49–69
- Grob CS, Danforth AL, Chopra GS, Hagerty M, McKay CR, Halberstadt AL, Greer GR (2011) Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. *Arch Gen Psychiatry* 68(1):71. <https://doi.org/10.1001/archgenpsychiatry.2010.116>
- Grof S, Goodman LE, Richards WA, Kurland AA (1973) LSD-assisted psychotherapy in patients with terminal cancer. *Int Pharmacopsychiatry* 8:129–144. <https://doi.org/10.1159/000467984>
- Grothe M, Heinsen H, Teipel SJ (2012) Atrophy of the cholinergic basal forebrain over the adult age range and in early stages of Alzheimer's disease. *Biol Psychiatry* 71(9):805–813. <https://doi.org/10.1016/j.biopsych.2011.06.019>
- Hafkemeijer A, van der Grond J, Rombouts SARB (2012) Imaging the default mode network in aging and dementia. *Biochim Biophys Acta* 1822(3):431–441. <https://doi.org/10.1016/j.bbadis.2011.07.008>
- Harvey JA, Quinn JL, Liu R, Aloyo VJ, Romano AG (2004) Selective remodeling of rabbit frontal cortex: relationship between 5-HT_{2A} receptor density and associative learning. *Psychopharmacology* 172(4):435–442. <https://doi.org/10.1007/s00213-003-1687-4>
- Hasselbalch SG, Madsen K, Svarer C, Pinborg LH, Holm S, Paulson OB, Waldemar G, Knudsen GM (2008) Reduced 5-HT_{2A} receptor binding in patients with mild cognitive impairment. *Neurobiol Aging* 29(12):1830–1838. <https://doi.org/10.1016/j.neurobiolaging.2007.04.011>
- He X, Qin W, Liu Y, Zhang X, Duan Y, Song J, Li K, Jiang T, Yu C (2014) Abnormal salience network in normal aging and in amnesic mild cognitive impairment and Alzheimer's disease. *Hum Brain Mapp* 35(7):3446–3464. <https://doi.org/10.1002/hbm.22414>
- He W, Goodkind D, Kowal P (2016) International population reports, P95/16-1, An aging world: 2015, U.S. Census Bureau. U.S. Government Publishing Office, Washington, DC
- Healy CJ (2021) The acute effects of classic psychedelics on memory in humans. *Psychopharmacology* 238(3):639–653. <https://doi.org/10.1007/s00213-020-05756-w>
- Herbert J, Lucassen PJ (2016) Depression as a risk factor for Alzheimer's disease: genes, steroids, cytokines and neurogenesis – what do we need to know? *Front Neuroendocrinol* 41:153–171. <https://doi.org/10.1016/j.yfrne.2015.12.001>
- Hoeffler CA, Klann E (2010) mTOR signaling: at the crossroads of plasticity, memory and disease. *Trends Neurosci* 33(2):67–75. <https://doi.org/10.1016/j.tins.2009.11.003>
- Holm P, Eittrup A, Klein AB, Santini MA, El-Sayed M, Elvang AB, Stensbøl TB, Mikkelsen JD, Knudsen GM, Aznar S (2010) Plaque deposition dependent decrease in 5-HT_{2A} serotonin receptor in AβPPswe/PS1dE9 amyloid overexpressing mice. *J Alzheimers Dis* 20(4):1201–1213. <https://doi.org/10.3233/JAD-2010-100117>
- Hutten NRPW, Mason NL, Dolder PC, Theunissen EL, Holze F, Liechti ME, Feilding A, Ramaekers JG, Kuypers KPC (2020) Mood and cognition after administration of low LSD doses in healthy volunteers: a placebo controlled dose-effect finding study. *Eur Neuropsychopharmacol* 41:81–91. <https://doi.org/10.1016/j.euroneuro.2020.10.002>
- Hutten NRPW, Mason NL, Dolder PC, Theunissen EL, Holze F, Liechti ME, Varghese N, Eckert A, Feilding A, Ramaekers JG, Kuypers KPC (2021) Low doses of LSD acutely increase BDNF blood plasma levels in healthy volunteers. *ACS Pharmacol Transl Sci* 4(2):461–466. <https://doi.org/10.1021/acspsci.0c00099>
- Ismail Z, Agüera-Ortiz L, Brodaty H, Cieslak A, Cummings J, Fischer CE, Gauthier S, Geda YE, Herrmann N, Kanji J, Lanctôt KL, Miller DS, Mortby ME, Onyike CU, Rosenberg PB, Smith EE, Smith GS, Sultzer DL, Lyketsos C, for the N. P. I. A. of the I. S. of to A. A. R. and T. (NPS-P. of ISTAART) (2017) The mild behavioral impairment checklist (MBI-C): a rating scale for neuropsychiatric symptoms in pre-dementia populations. *J Alzheimers Dis* 56(3):929–938. <https://doi.org/10.3233/JAD-160979>
- Jack CR Jr, Wiste HJ, Botha H, Weigand SD, Thorneau TM, Knopman DS, Graff-Radford J, Jones DT, Ferman TJ, Boeve BF (2019) The bivariate distribution of amyloid-β and tau: relationship with established neurocognitive clinical syndromes. *Brain* 142(10):3230–3242

- Jarvik ME, Abramson HA, Hirsch MW (1955) Lysergic acid diethylamide (LSD-25): VI. Effect upon recall and recognition of various stimuli. *J Psychol* 39(2):443–454. <https://doi.org/10.1080/00223980.1955.9916194>
- Jaworski J, Sheng M (2006) The growing role of mTOR in neuronal development and plasticity. *Mol Neurobiol* 34(3):205–219. <https://doi.org/10.1385/MN:34:3:205>
- Jefsen OH, Elfving B, Wegener G, Müller HK (2021) Transcriptional regulation in the rat prefrontal cortex and hippocampus after a single administration of psilocybin. *J Psychopharmacol* 35(4):483–493. <https://doi.org/10.1177/0269881120959614>
- Johnson MW, Richards WA, Griffiths RR (2008) Human hallucinogen research: guidelines for safety. *J Psychopharmacol* 22(6):603–620
- Johnson MW, Garcia-Romeu A, Cosimano MP, Griffiths RR (2014) Pilot study of the 5-HT_{2A} agonist psilocybin in the treatment of tobacco addiction. *J Psychopharmacol* 28(11):983–992
- Johnson MW, Griffiths RR, Hendricks PS, Henningfield JE (2018) The abuse potential of medical psilocybin according to the 8 factors of the controlled substances act. *Neuropharmacology* 142:143–166
- Joie RL, Perrotin A, Barré L, Hommet C, Mézence F, Ibazizene M, Camus V, Abbas A, Landeau B, Guilloteau D, Sayette VL, Eustache F, Desgranges B, Chételat G (2012) Region-specific hierarchy between atrophy, hypometabolism, and β -amyloid (A β) load in Alzheimer's disease dementia. *J Neurosci* 32(46):16265–16273. <https://doi.org/10.1523/JNEUROSCI.2170-12.2012>
- Karran E, Hardy J (2014) A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease. *Ann Neurol* 76(2):185–205. <https://doi.org/10.1002/ana.24188>
- Karran E, Mercken M, Strooper BD (2011) The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. *Nat Rev Drug Discov* 10(9):698–712. <https://doi.org/10.1038/nrd3505>
- Karttunen K, Karppi P, Hiltunen A, Vanhanen M, Välimäki T, Martikainen J, Valtonen H, Sivenius J, Soininen H, Hartikainen S, Suhonen J, Pirttilä T (2011) Neuropsychiatric symptoms and quality of life in patients with very mild and mild Alzheimer's disease. *Int J Geriatr Psychiatry* 26(5):473–482. <https://doi.org/10.1002/gps.2550>
- Killin LOJ, Starr JM, Shiue IJ, Russ TC (2016) Environmental risk factors for dementia: a systematic review. *BMC Geriatr* 16(1):175. <https://doi.org/10.1186/s12877-016-0342-y>
- Kim SYH (2011) The ethics of informed consent in Alzheimer disease research. *Nat Rev Neurol* 7(7):410–414. <https://doi.org/10.1038/nrneurol.2011.76>
- King AR, Martin IL, Seymour KA (1972) Reversal learning facilitated by a single injection of lysergic acid diethylamide (LSD 25) in the rat. *Br J Pharmacol* 45(1):161P–162P
- Kinney JW, Bemiller SM, Murtishaw AS, Leisgang AM, Salazar AM, Lamb BT (2018) Inflammation as a central mechanism in Alzheimer's disease. *Alzheimer's Dementia Transl Res Clin Interv* 4:575–590. <https://doi.org/10.1016/j.trci.2018.06.014>
- Klaassens BL, van Gerven J, van der Grond J, de Vos F, Möller C, Rombouts SA (2017) Diminished posterior precuneus connectivity with the default mode network differentiates normal aging from Alzheimer's disease. *Front Aging Neurosci* 9:97
- Knopman DS, Jones DT, Greicius MD (2021) Failure to demonstrate efficacy of aducanumab: an analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019. *Alzheimers Dement* 17(4):696–701. <https://doi.org/10.1002/alz.12213>
- Kunkle BW, Grenier-Boley B, Sims R, Bis JC, Damotte V, Naj AC, Boland A, Vronskaya M, van der Lee SJ, Amlie-Wolf A, Bellenguez C, Frizatti A, Chouraki V, Martin ER, Sleegers K, Badarinarayan N, Jakobsdottir J, Hamilton-Nelson KL, Moreno-Grau S et al (2019) Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates A β , tau, immunity and lipid processing. *Nat Genet* 51(3):414–430. <https://doi.org/10.1038/s41588-019-0358-2>
- Lai MK, Tsang SW, Alder JT, Keene J, Hope T, Esiri MM, Francis PT, Chen CP (2005) Loss of serotonin 5-HT_{2A} receptors in the postmortem temporal cortex correlates with rate of cognitive

- decline in Alzheimer's disease. *Psychopharmacology* 179(3):673–677. <https://doi.org/10.1007/s00213-004-2077-2>
- Lancôt KL, Amatniek J, Ancoli-Israel S, Arnold SE, Ballard C, Cohen-Mansfield J, Ismail Z, Lyketsos C, Miller DS, Musiek E, Osorio RS, Rosenberg PB, Satlin A, Steffens D, Tariot P, Bain LJ, Carrillo MC, Hendrix JA, Jurgens H, Boot B (2017) Neuropsychiatric signs and symptoms of Alzheimer's disease: new treatment paradigms. *Alzheimer's Dementia Transl Res Clin Interv* 3(3):440–449. <https://doi.org/10.1016/j.trci.2017.07.001>
- Langs RJ (1967) Stability of earliest memories under LSD-25 AND PLACEBO. *J Nerv Ment Dis* 144(3):171–184
- Leoutsakos J-MS, Forrester SN, Lyketsos CG, Smith GS (2015) Latent classes of neuropsychiatric symptoms in NACC controls and conversion to mild cognitive impairment or dementia. *J Alzheimers Dis* 48(2):483–493. <https://doi.org/10.3233/JAD-150421>
- Li L-B, Zhang L, Sun Y-N, Han L-N, Wu Z-H, Zhang Q-J, Liu J (2015) Activation of serotonin_{2A} receptors in the medial septum-diagonal band of Broca complex enhanced working memory in the hemiparkinsonian rats. *Neuropharmacology* 91:23–33. <https://doi.org/10.1016/j.neuropharm.2014.11.025>
- Lima da Cruz RV, Moulin TC, Petiz LL, Leão RN (2018) A single dose of 5-MeO-DMT stimulates cell proliferation, neuronal survivability, morphological and functional changes in adult mice ventral dentate gyrus. *Front Mol Neurosci* 11. <https://doi.org/10.3389/fnmol.2018.00312>
- Liu Y, Yoo M-J, Savonenko A, Stirling W, Price DL, Borchelt DR, Mamounas L, Lyons WE, Blue ME, Lee MK (2008) Amyloid pathology is associated with progressive monoaminergic neurodegeneration in a transgenic mouse model of Alzheimer's disease. *J Neurosci* 28(51):13805–13814. <https://doi.org/10.1523/JNEUROSCI.4218-08.2008>
- Lyu C, Greb AC, Cameron LP, Wong JM, Barragan EV, Wilson PC, Burbach KF, Soltanzadeh Zarandi S, Sood A, Paddy MR, Duim WC, Dennis MY, McAllister AK, Ori-McKenney KM, Gray JA, Olson DE (2018) Psychedelics promote structural and functional neural plasticity. *Cell Rep* 23(11):3170–3182. <https://doi.org/10.1016/j.celrep.2018.05.022>
- Lyketsos CG, Lopez O, Jones B, Fitzpatrick AL, Breitner J, DeKosky S (2002) Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study. *JAMA* 288(12):1475. <https://doi.org/10.1001/jama.288.12.1475>
- Lyketsos CG, Colenda CC, Beck C, Blank K, Doraiswamy MP, Kalunian DA, Yaffe K (2006) Position statement of the American Association for Geriatric Psychiatry regarding principles of care for patients with dementia resulting from Alzheimer Disease. *Am J Geriatr Psychiatry* 14(7):561–573. <https://doi.org/10.1097/01.JGP.0000221334.65330.55>
- Lyketsos CG, Carrillo MC, Ryan JM, Khachaturian AS, Trzepacz P, Amatniek J, Cedarbaum J, Brashear R, Miller DS (2011) Neuropsychiatric symptoms in Alzheimer's disease. *Alzheimers Dement* 7(5):532–539. <https://doi.org/10.1016/j.jalz.2011.05.2410>
- MacLean KA, Johnson MW, Griffiths RR (2011) Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness. *J Psychopharmacol* 25(11):1453–1461
- Madsen MK, Fisher PM, Stenbæk DS, Kristiansen S, Burmester D, Lehel S, Pálenček T, Kuchař M, Svarer C, Ozenne B, Knudsen GM (2020) A single psilocybin dose is associated with long-term increased mindfulness, preceded by a proportional change in neocortical 5-HT_{2A} receptor binding. *Eur Neuropsychopharmacol* 33:71–80. <https://doi.org/10.1016/j.euroneuro.2020.02.001>
- Marnier L, Frokjaer VG, Kalbitzer J, Lehel S, Madsen K, Baaré WF, Knudsen GM, Hasselbalch SG (2012) Loss of serotonin 2A receptors exceeds loss of serotonergic projections in early Alzheimer's disease: a combined [11C] DASB and [18F] altanserin-PET study. *Neurobiol Aging* 33(3):479–487
- Marucci G, Buccioni M, Ben DD, Lambertucci C, Volpini R, Amenta F (2021) Efficacy of acetylcholinesterase inhibitors in Alzheimer's disease. *Neuropharmacology* 190:108352. <https://doi.org/10.1016/j.neuropharm.2020.108352>

- Maslah E, Mallory M, Alford M, DeTeresa R, Hansen LA, McKeel DW, Morris JC (2001) Altered expression of synaptic proteins occurs early during progression of Alzheimer's disease. *Neurology* 56(1):127–129. <https://doi.org/10.1212/WNL.56.1.127>
- Mason NL, Kuypers KPC, Müller F, Reckweg J, Tse DHY, Toennes SW, Hutten NRPW, Jansen JFA, Stiers P, Feilding A, Ramaekers JG (2020) Me, myself, bye: regional alterations in glutamate and the experience of ego dissolution with psilocybin. *Neuropsychopharmacology* 45(12):2003–2011. <https://doi.org/10.1038/s41386-020-0718-8>
- Mecca AP (2019) Icii - AD molecular: molecular imaging of Alzheimer's disease: PET imaging of neurotransmitter systems. In: Becker JT, Cohen AD (eds) *Progress in molecular biology and translational science*, vol vol 165. Academic Press, pp 139–165. <https://doi.org/10.1016/bs.pmbts.2019.04.003>
- Mevel K, Chételat G, Eustache F, Desgranges B (2011) The default mode network in healthy aging and Alzheimer's disease. *Int J Alzheimers Dis* 2011:e535816. <https://doi.org/10.4061/2011/535816>
- Michaelsen K, Zagrebelsky M, Berndt-Huch J, Polack M, Buschler A, Sendtner M, Korte M (2010) Neurotrophin receptors TrkB.T1 and p75NTR cooperate in modulating both functional and structural plasticity in mature hippocampal neurons. *Eur J Neurosci* 32(11):1854–1865. <https://doi.org/10.1111/j.1460-9568.2010.07460.x>
- Miguel-Álvarez M, Santos-Lozano A, Sanchis-Gomar F, Fiuza-Luces C, Pareja-Galeano H, Garatachea N, Lucia A (2015) Non-steroidal anti-inflammatory drugs as a treatment for Alzheimer's disease: a systematic review and meta-analysis of treatment effect. *Drugs Aging* 32(2):139–147
- Minichiello L (2009) TrkB signalling pathways in LTP and learning. *Nat Rev Neurosci* 10(12):850–860. <https://doi.org/10.1038/nrn2738>
- Mintun MA, Lo AC, Duggan Evans C, Wessels AM, Ardayfio PA, Andersen SW, Shcherbinin S, Sparks J, Sims JR, Brys M, Apostolova LG, Salloway SP, Skovronsky DM (2021) Donanemab in early Alzheimer's disease. *N Engl J Med* 384(18):1691–1704. <https://doi.org/10.1056/NEJMoa2100708>
- Nau F Jr, Yu B, Martin D, Nichols CD (2013) Serotonin 5-HT 2A receptor activation blocks TNF- α mediated inflammation in vivo. *PLoS One* 8(10):e75426
- Nelson JC, Devanand DP (2011) A systematic review and meta-analysis of placebo-controlled antidepressant studies in people with depression and dementia. *J Am Geriatr Soc* 59(4):577–585. <https://doi.org/10.1111/j.1532-5415.2011.03355.x>
- Nichols DE (2016) Psychedelics. *Pharmacol Rev* 68(2):264–355. <https://doi.org/10.1124/pr.115.011478>
- Nichols DE (2020) Psilocybin: from ancient magic to modern medicine. *J Antibiot* 73(10):679–686. <https://doi.org/10.1038/s41429-020-0311-8>
- Nichols CD, Sanders-Bush E (2002) A single dose of lysergic acid diethylamide influences gene expression patterns within the mammalian brain. *Neuropsychopharmacology* 26(5):634–642. [https://doi.org/10.1016/S0893-133X\(01\)00405-5](https://doi.org/10.1016/S0893-133X(01)00405-5)
- Nichols CD, Garcia EE, Sanders-Bush E (2003) Dynamic changes in prefrontal cortex gene expression following lysergic acid diethylamide administration. *Mol Brain Res* 111(1):182–188. [https://doi.org/10.1016/S0169-328X\(03\)00029-9](https://doi.org/10.1016/S0169-328X(03)00029-9)
- Noorani T, Garcia-Romeu A, Swift TC, Griffiths RR, Johnson MW (2018) Psychedelic therapy for smoking cessation: qualitative analysis of participant accounts. *J Psychopharmacol* 32(7):756–769. <https://doi.org/10.1177/0269881118780612>
- Olson DE (2018) Psychoplastogens: a promising class of plasticity-promoting neurotherapeutics. *J Exp Neurosci* 12:1179069518800508. <https://doi.org/10.1177/1179069518800508>
- Olson DE (2021) The subjective effects of psychedelics may not be necessary for their enduring therapeutic effects. *ACS Pharmacol Transl Sci* 4(2):563–567. <https://doi.org/10.1021/acspsci.0c00192>
- Ossenkoppelle R, Schonhaut DR, Schöll M, Lockhart SN, Ayakta N, Baker SL, O'Neil JP, Janabi M, Lazaris A, Cantwell A, Vogel J, Santos M, Miller ZA, Bettcher BM, Vessel KA,

- Kramer JH, Gorno-Tempini ML, Miller BL, Jagust WJ, Rabinovici GD (2016) Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease. *Brain* 139 (5):1551–1567. <https://doi.org/10.1093/brain/aww027>
- Ozben T, Ozben S (2019) Neuro-inflammation and anti-inflammatory treatment options for Alzheimer's disease. *Clin Biochem* 72:87–89. <https://doi.org/10.1016/j.clinbiochem.2019.04.001>
- Palhano-Fontes F, Barreto D, Onias H, Andrade KC, Novaes MM, Pessoa JA, Mota-Rolim SA, Osório FL, Sanches R, dos Santos RG, Tófoli LF, Silveira GO, Yonamine M, Riba J, Santos FR, Silva-Junior AA, Alchieri JC, Galvão-Coelho NL, Lobão-Soares B et al (2019) Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial. *Psychol Med* 49(4):655–663. <https://doi.org/10.1017/S0033291718001356>
- Palmqvist S, Schöll M, Strandberg O, Mattsson N, Stomrud E, Zetterberg H, Blennow K, Landau S, Jagust W, Hansson O (2017) Earliest accumulation of β -amyloid occurs within the default-mode network and concurrently affects brain connectivity. *Nat Commun* 8(1):1214. <https://doi.org/10.1038/s41467-017-01150-x>
- Palop JJ, Mucke L (2016) Network abnormalities and interneuron dysfunction in Alzheimer disease. *Nat Rev Neurosci* 17(12):777–792. <https://doi.org/10.1038/nrn.2016.141>
- Pasquini L, Rahmani F, Maleki-Balajoo S, La Joie R, Zarei M, Sorg C, Drzezga A, Tahmasian M (2019) Medial temporal lobe disconnection and hyperexcitability across Alzheimer's disease stages. *J Alzheimer's Dis Rep* 3(1):103–112. <https://doi.org/10.3233/ADR-190121>
- Pasquini L, Palhano-Fontes F, Araujo DB (2020) Subacute effects of the psychedelic ayahuasca on the salience and default mode networks. *J Psychopharmacol* 34(6):623–635. <https://doi.org/10.1177/0269881120909409>
- Peng S, Wu J, Mufson EJ, Fahnstock M (2005) Precursor form of brain-derived neurotrophic factor and mature brain-derived neurotrophic factor are decreased in the pre-clinical stages of Alzheimer's disease. *J Neurochem* 93(6):1412–1421. <https://doi.org/10.1111/j.1471-4159.2005.03135.x>
- Peters ME, Schwartz S, Han D, Rabins PV, Steinberg M, Tschanz JT, Lyketsos CG (2015) Neuropsychiatric symptoms as predictors of progression to severe Alzheimer's dementia and death: the cache county dementia progression study. *Am J Psychiatr* 172(5):460–465. <https://doi.org/10.1176/appi.ajp.2014.14040480>
- Pokorny T, Duerler P, Seifritz E, Vollenweider FX, Preller KH (2020) LSD acutely impairs working memory, executive functions, and cognitive flexibility, but not risk-based decision-making. *Psychol Med* 50(13):2255–2264. <https://doi.org/10.1017/S0033291719002393>
- Preller KH, Duerler P, Burt JB, Ji JL, Adkinson B, Stämpfli P, Seifritz E, Repovš G, Krystal JH, Murray JD, Anticevic A, Vollenweider FX (2020) Psilocybin induces time-dependent changes in global functional connectivity. *Biol Psychiatry* 88(2):197–207. <https://doi.org/10.1016/j.biopsych.2019.12.027>
- Putchá D, Brickhouse M, O'Keefe K, Sullivan C, Rentz D, Marshall G, Dickerson B, Sperling R (2011) Hippocampal hyperactivation associated with cortical thinning in Alzheimer's disease signature regions in non-demented elderly adults. *J Neurosci* 31(48):17680–17688. <https://doi.org/10.1523/JNEUROSCI.4740-11.2011>
- Raval NR, Johansen A, Donovan LL, Ros NF, Ozenne B, Hansen HD, Knudsen GM (2021) A single dose of psilocybin increases synaptic density and decreases 5-HT_{2A} receptor density in the pig brain. *Int J Mol Sci* 22(2):835. <https://doi.org/10.3390/ijms22020835>
- Reiff CM, Richman EE, Nemeroff CB, Carpenter LL, Widge AS, Rodriguez CI, Kalin NH, McDonald WM (2020) Psychedelics and psychedelic-assisted psychotherapy. *Am J Psychiatr* 177(5):391–410. <https://doi.org/10.1176/appi.ajp.2019.19010035>
- Revenge MF, Zhu B, Guevara CA, Naler LB, Saunders JM, Zhou Z, Toneatti R, Sierra S, Wolstenholme JT, Beardsley PM, Huntley GW, Lu C, González-Maeso J (2021) Prolonged epigenetic and synaptic plasticity alterations following single exposure to a psychedelic in mice. *BioRxiv* 2021(02):24.432725. <https://doi.org/10.1101/2021.02.24.432725>

- Rice L, Bisdas S (2017) The diagnostic value of FDG and amyloid PET in Alzheimer's disease—a systematic review. *Eur J Radiol* 94:16–24. <https://doi.org/10.1016/j.ejrad.2017.07.014>
- Rich JB, Rasmusson DX, Folstein MF, Carson KA, Kawas C, Brandt J (1995) Nonsteroidal anti-inflammatory drugs in Alzheimer's disease. *Neurology* 45(1):51–55. <https://doi.org/10.1212/WNL.45.1.51>
- Richards WA, Rhead JC, DiLeo FB, Yensen R, Kurland AA (1977) The peak experience variable in DPT-assisted psychotherapy with cancer patients. *J Psychedelic Drugs* 9(1):1–10
- Romano AG, Quinn JL, Li L, Dave KD, Schindler EA, Aloyo VJ, Harvey JA (2010) Intrahippocampal LSD accelerates learning and desensitizes the 5-HT_{2A} receptor in the rabbit, Romano et al. *Psychopharmacology* 212(3):441–448. <https://doi.org/10.1007/s00213-010-2004-7>
- Roseman L, Nutt DJ, Carhart-Harris RL (2018) Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression. *Front Pharmacol* 8:974
- Rosenberg PB, Martin BK, Frangakis C, Mintzer JE, Weintraub D, Porsteinson AP, Schneider LS, Rabins PV, Munro CA, Meinert CL, Lyketsos CG, Drye LT (2010) Sertraline for the treatment of depression in Alzheimer disease. *Am J Geriatr Psychiatry* 18(2):136–145. <https://doi.org/10.1097/JGP.0b013e3181c796eb>
- Ross S, Bossis A, Guss J, Agin-Liebes G, Malone T, Cohen B, Mennenga SE, Belser A, Kalliontzki K, Babb J, Su Z, Corby P, Schmidt BL (2016) Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. *J Psychopharmacol* 30(12):1165–1180. <https://doi.org/10.1177/0269881116675512>
- Ruthirakuhan M, Herrmann N, Vieira D, Gallagher D, Lanctôt KL (2019) The roles of apathy and depression in predicting Alzheimer disease: a longitudinal analysis in older adults with mild cognitive impairment. *Am J Geriatr Psychiatry* 27(8):873–882. <https://doi.org/10.1016/j.jagp.2019.02.003>
- Sala Frigerio C, De Strooper B (2016) Alzheimer's disease mechanisms and emerging roads to novel therapeutics. *Annu Rev Neurosci* 39(1):57–79. <https://doi.org/10.1146/annurev-neuro-070815-014015>
- Sampedro F, de la Fuente Revenga M, Valle M, Roberto N, Domínguez-Clavé E, Elices M, Luna LE, Crippa JAS, Hallak JEC, de Araujo DB, Friedlander P, Barker SA, Álvarez E, Soler J, Pascual JC, Feilding A, Riba J (2017) Assessing the psychedelic “after-glow” in Ayahuasca users: post-acute neurometabolic and functional connectivity changes are associated with enhanced mindfulness capacities. *Int J Neuropsychopharmacol* 20(9):698–711. <https://doi.org/10.1093/ijnp/pyx036>
- Scarmeas N, Brandt J, Albert M, Hadjigeorgiou G, Papadimitriou A, Dubois B, Sarazin M, Devanand D, Honig L, Marder K, Bell K, Wegesin D, Blacker D, Stern Y (2005) Delusions and hallucinations are associated with worse outcome in Alzheimer disease. *Arch Neurol* 62(10). <https://doi.org/10.1001/archneur.62.10.1601>
- Schindler EAD, Sewell RA, Gottschalk CH, Luddy C, Flynn LT, Lindsey H, Pittman BP, Cozzi NV, D'Souza DC (2021) Exploratory controlled study of the migraine-suppressing effects of psilocybin. *Neurotherapeutics* 18(1):534–543. <https://doi.org/10.1007/s13311-020-00962-y>
- Schmid Y, Liechi ME (2018) Long-lasting subjective effects of LSD in normal subjects. *Psychopharmacology* 235(2):535–545. <https://doi.org/10.1007/s00213-017-4733-3>
- Schott BH, Seidenbecher CI, Richter S, Wüstenberg T, Debska-Vielhaber G, Schubert H, Heinze H-J, Richardson-Klavehn A, Düzel E (2011) Genetic variation of the serotonin 2a receptor affects hippocampal novelty processing in humans. *PLoS One* 6(1):e15984. <https://doi.org/10.1371/journal.pone.0015984>
- Schwindt GC, Chaudhary S, Crane D, Ganda A, Masellis M, Grady CL, Stefanovic B, Black SE (2013) Modulation of the default-mode network between rest and task in Alzheimer's disease. *Cereb Cortex* 23(7):1685–1694. <https://doi.org/10.1093/cercor/bhs160>
- Selkoe DJ (2002) Alzheimer's disease is a synaptic failure. *Science* 298(5594):789–791. <https://doi.org/10.1126/science.1074069>

- Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT (2011a) Neuropathological alterations in Alzheimer disease. *Cold Spring Harb Perspect Med* 1(1):a006189. <https://doi.org/10.1101/cshperspect.a006189>
- Serrano-Pozo A, Mielke ML, Gómez-Isla T, Betensky RA, Growdon JH, Frosch MP, Hyman BT (2011b) Reactive glia not only associates with plaques but also parallels tangles in Alzheimer's disease. *Am J Pathol* 179(3):1373–1384. <https://doi.org/10.1016/j.ajpath.2011.05.047>
- Sestieri C, Corbetta M, Romani GL, Shulman GL (2011) Episodic memory retrieval, parietal cortex, and the default mode network: functional and topographic analyses. *J Neurosci* 31(12):4407–4420. <https://doi.org/10.1523/JNEUROSCI.3335-10.2011>
- Sevigny J, Chiao P, Bussière T, Weinreb PH, Williams L, Maier M, Dunstan R, Salloway S, Chen T, Ling Y, O'Gorman J, Qian F, Arastu M, Li M, Chollate S, Brennan MS, Quintero-Monzon O, Scannevin RH, Arnold HM et al (2016) The antibody aducanumab reduces A β plaques in Alzheimer's disease. *Nature* 537(7618):50–56. <https://doi.org/10.1038/nature19323>
- Shao L-X, Liao C, Gregg I, Davoudian PA, Savalia NK, Delagarza K, Kwan AC (2021) Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo. *Neuron*. <https://doi.org/10.1016/j.neuron.2021.06.008>
- Shin I-S, Carter M, Masterman D, Fairbanks L, Cummings JL (2005) Neuropsychiatric symptoms and quality of life in Alzheimer disease. *Am J Geriatr Psychiatry* 13(6):469–474. <https://doi.org/10.1097/00019442-200506000-00005>
- Shoghi-Jadid K, Small GW, Agdeppa ED, Kepe V, Ercoli LM, Siddarth P, Read S, Satyamurthy N, Petric A, Huang S-C, Barrio JR (2002) Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. *Am J Geriatr Psychiatry* 10(1):24–35. <https://doi.org/10.1097/00019442-200201000-00004>
- Smigielski L, Kometer M, Scheidegger M, Krähenmann R, Huber T, Vollenweider FX (2019a) Characterization and prediction of acute and sustained response to psychedelic psilocybin in a mindfulness group retreat. *Sci Rep* 9(1):14914. <https://doi.org/10.1038/s41598-019-50612-3>
- Smigielski L, Scheidegger M, Kometer M, Vollenweider FX (2019b) Psilocybin-assisted mindfulness training modulates self-consciousness and brain default mode network connectivity with lasting effects. *NeuroImage* 196:207–215. <https://doi.org/10.1016/j.neuroimage.2019.04.009>
- Smith GS, Barrett FS, Joo JH, Nassery N, Savonenko A, Sodums DJ, Marano CM, Munro CA, Brandt J, Kraut MA, Zhou Y, Wong DF, Workman CI (2017) Molecular imaging of serotonin degeneration in mild cognitive impairment. *Neurobiol Dis* 105:33–41. <https://doi.org/10.1016/j.nbd.2017.05.007>
- Soto M, Andrieu S, Nourhashemi F, Ousset PJ, Ballard C, Robert P, Vellas B, Lyketsos CG, Rosenberg PB (2015) Medication development for agitation and aggression in Alzheimer disease: review and discussion of recent randomized clinical trial design. *Int Psychogeriatr* 27(2):181–197. <https://doi.org/10.1017/S1041610214001720>
- Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR, Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E, Stern Y, Yaffe K, Carrillo MC, Thies B, Morrison-Bogorad M et al (2011) Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement* 7(3):280–292. <https://doi.org/10.1016/j.jalz.2011.03.003>
- Steinberg M, Shao H, Zandi P, Lyketsos CG, Welsh-Bohmer KA, Norton MC, Breitner JCS, Steffens DC, Tschanz JT (2008) Point and 5-year period prevalence of neuropsychiatric symptoms in dementia: the Cache County Study. *Int J Geriatr Psychiatry* 23(2):170–177. <https://doi.org/10.1002/gps.1858>
- Stewart WF, Kawas C, Corrada M, Metter EJ (1997) Risk of Alzheimer's disease and duration of NSAID use. *Neurology* 48(3):626–632. <https://doi.org/10.1212/WNL.48.3.626>
- Stopford CL, Snowden JS, Thompson JC, Neary D (2008) Variability in cognitive presentation of Alzheimer's disease. *Cortex* 44(2):185–195. <https://doi.org/10.1016/j.cortex.2005.11.002>

- Swift TC, Belser AB, Agin-Liebes G, Devenot N, Terrana S, Friedman HL, Guss J, Bossis AP, Ross S (2017) Cancer at the dinner table: experiences of psilocybin-assisted psychotherapy for the treatment of cancer-related distress. *J Humanist Psychol* 57(5):488–519
- Szabo A, Kovacs A, Frecska E, Rajnavolgyi E (2014) Psychedelic N, N-dimethyltryptamine and 5-methoxy-N, N-dimethyltryptamine modulate innate and adaptive inflammatory responses through the sigma-1 receptor of human monocyte-derived dendritic cells. *PLoS One* 9(8): e106533
- Sze C-I, Troncoso JC, Kawas C, Mouton P, Price DL, Martin LJ (1997) Loss of the presynaptic vesicle protein synaptophysin in hippocampus correlates with cognitive decline in Alzheimer disease. *J Neuropathol Exp Neurol* 56(8):933–944. <https://doi.org/10.1097/00005072-199708000-00011>
- Tang L, Wang Y, Chen Y, Chen L, Zheng S, Bao M, Xiang J, Luo H, Li J, Li Y (2017) The association between 5HT2A T102C and behavioral and psychological symptoms of dementia in Alzheimer's disease: a meta-analysis. *Biomed Res Int* 2017:e5320135. <https://doi.org/10.1155/2017/5320135>
- Tanila H (2017) The role of BDNF in Alzheimer's disease. *Neurobiol Dis* 97:114–118. <https://doi.org/10.1016/j.nbd.2016.05.008>
- Tanzi RE (2012) The genetics of Alzheimer disease. *Cold Spring Harb Perspect Med* 2(10): a006296. <https://doi.org/10.1101/cshperspect.a006296>
- Tayeb HO, Yang HD, Price BH, Tarazi FI (2012) Pharmacotherapies for Alzheimer's disease: beyond cholinesterase inhibitors. *Pharmacol Ther* 134(1):8–25. <https://doi.org/10.1016/j.pharmthera.2011.12.002>
- Theofilas P, Ehrenberg AJ, Dunlop S, Di Lorenzo Alho AT, Nguy A, Leite REP, Rodriguez RD, Mejia MB, Suemoto CK, Ferretti-Rebustini REDL, Polichiso L, Nascimento CF, Seeley WW, Nitrini R, Pasqualucci CA, Jacob Filho W, Rueb U, Neuhaus J, Heinsen H, Grinberg LT (2017) Locus coeruleus volume and cell population changes during Alzheimer's disease progression: a stereological study in human postmortem brains with potential implication for early-stage biomarker discovery. *Alzheimers Dement* 13(3):236–246. <https://doi.org/10.1016/j.jalz.2016.06.2362>
- Tomasi D, Volkow ND (2012) Aging and functional brain networks. *Mol Psychiatry* 17(5):549–558. <https://doi.org/10.1038/mp.2011.81>
- Tramutola A, Lanzillotta C, Domenico FD (2017) Targeting mTOR to reduce Alzheimer-related cognitive decline: from current hits to future therapies. *Expert Rev Neurother* 17(1):33–45. <https://doi.org/10.1080/14737175.2017.1244482>
- Tromp D, Dufour A, Lithfous S, Pebayle T, Després O (2015) Episodic memory in normal aging and Alzheimer disease: insights from imaging and behavioral studies. *Ageing Res Rev* 24:232–262. <https://doi.org/10.1016/j.arr.2015.08.006>
- Tsybko AS, Ilchibaeva TV, Filimonova EA, Eremin DV, Popova NK, Naumenko VS (2020) The chronic treatment with 5-HT2A receptor agonists affects the behavior and the BDNF system in mice. *Neurochem Res* 45(12):3059–3075. <https://doi.org/10.1007/s11064-020-03153-5>
- Vann Jones SA, O'Kelly A (2020) Psychedelics as a treatment for Alzheimer's disease dementia. *Front Synapt Neurosci* 12. <https://doi.org/10.3389/fnsyn.2020.00034>
- Versijpt J, Van Laere KJ, Dumont F, Decoo D, Vandecapelle M, Santens P, Goethals I, Audenaert K, Slegers G, Dierckx RA, Korf J (2003) Imaging of the 5-HT2A system: age-, gender-, and Alzheimer's disease-related findings. *Neurobiol Aging* 24(4):553–561. [https://doi.org/10.1016/S0197-4580\(02\)00137-9](https://doi.org/10.1016/S0197-4580(02)00137-9)
- Wang W-Y, Tan M-S, Yu J-T, Tan L (2015) Role of pro-inflammatory cytokines released from microglia in Alzheimer's disease. *Ann Transl Med* 3(10). <https://doi.org/10.3978/j.issn.2305-5839.2015.03.49>
- Watts R, Day C, Krzanowski J, Nutt D, Carhart-Harris R (2017) Patients' accounts of increased "connectedness" and "acceptance" after psilocybin for treatment-resistant depression. *J Humanist Psychol* 57(5):520–564. <https://doi.org/10.1177/0022167817709585>

- Weintraub S, Wicklund AH, Salmon DP (2012) The neuropsychological profile of Alzheimer disease. *Cold Spring Harb Perspect Med* 2(4):a006171. <https://doi.org/10.1101/cshperspect.a006171>
- Williams GV, Rao SG, Goldman-Rakic PS (2002) The physiological role of 5-HT_{2A} receptors in working memory. *J Neurosci* 22(7):2843–2854. <https://doi.org/10.1523/JNEUROSCI.22-07-02843.2002>
- Wimo A, Ballard C, Brayne C, Gauthier S, Handels R, Jones RW, Jonsson L, Khachaturian AS, Kramberger M (2014) Health economic evaluation of treatments for Alzheimer's disease: impact of new diagnostic criteria. *J Intern Med* 275(3):304–316. <https://doi.org/10.1111/joim.12167>
- Wittmann M, Carter O, Hasler F, Cahn BR, Grimberg U, Spring P, Hell D, Flohr H, Vollenweider FX (2007) Effects of psilocybin on time perception and temporal control of behaviour in humans. *J Psychopharmacol* 21(1):50–64. <https://doi.org/10.1177/0269881106065859>
- Yaden DB, Griffiths RR (2021) The subjective effects of psychedelics are necessary for their enduring therapeutic effects. *ACS Pharmacol Transl Sci* 4(2):568–572. <https://doi.org/10.1021/acspsci.0c00194>
- Yu B, Becnel J, Zerfaoui M, Rohatgi R, Boulares AH, Nichols CD (2008) Serotonin 5-HT_{2A} receptor activation suppresses TNF- α -induced inflammation with extraordinary potency. *J Pharmacol Exp Ther*. <https://doi.org/10.1124/jpet.108.143461>
- Yuede CM, Wallace CE, Davis TA, Gardiner WD, Hettinger JC, Edwards HM, Hendrix RD, Doherty BM, Yuede KM, Burstein ES, Cirrito JR (2021) Pimavanserin, a 5HT_{2A} receptor inverse agonist, rapidly suppresses A β production and related pathology in a mouse model of Alzheimer's disease. *J Neurochem* 156(5):658–673. <https://doi.org/10.1111/jnc.15260>
- Yuki D, Sugiura Y, Zaima N, Akatsu H, Takei S, Yao I, Maesako M, Kinoshita A, Yamamoto T, Kon R, Sugiyama K, Setou M (2014) DHA-PC and PSD-95 decrease after loss of synaptophysin and before neuronal loss in patients with Alzheimer's disease. *Sci Rep* 4(1):7130. <https://doi.org/10.1038/srep07130>
- Zhang G, Stackman RW Jr (2015) The role of serotonin 5-HT_{2A} receptors in memory and cognition. *Front Pharmacol* 6:225
- Zhang G, Ásgeirsdóttir HN, Cohen SJ, Munchow AH, Barrera MP, Stackman RW (2013) Stimulation of serotonin 2A receptors facilitates consolidation and extinction of fear memory in C57BL/6J mice. *Neuropharmacology* 64:403–413. <https://doi.org/10.1016/j.neuropharm.2012.06.007>
- Zhang G, Cinalli D, Cohen SJ, Knapp KD, Rios LM, Martínez-Hernández J, Luján R, Stackman RW (2016) Examination of the hippocampal contribution to serotonin 5-HT_{2A} receptor-mediated facilitation of object memory in C57BL/6J mice. *Neuropharmacology* 109:332–340. <https://doi.org/10.1016/j.neuropharm.2016.04.033>
- Zhao Q-F, Tan L, Wang H-F, Jiang T, Tan M-S, Tan L, Xu W, Li J-Q, Wang J, Lai T-J, Yu J-T (2016) The prevalence of neuropsychiatric symptoms in Alzheimer's disease: systematic review and meta-analysis. *J Affect Disord* 190:264–271. <https://doi.org/10.1016/j.jad.2015.09.069>
- Zhou J, Seeley WW (2014) Network dysfunction in Alzheimer's disease and frontotemporal dementia: implications for psychiatry. *Biol Psychiatry* 75(7):565–573. <https://doi.org/10.1016/j.biopsych.2014.01.020>
- Zotova E, Nicoll JA, Kalaria R, Holmes C, Boche D (2010) Inflammation in Alzheimer's disease: relevance to pathogenesis and therapy. *Alzheimers Res Ther* 2(1):1. <https://doi.org/10.1186/alzrt24>